CN118176017A - Combined medicine for treating tumor - Google Patents
Combined medicine for treating tumor Download PDFInfo
- Publication number
- CN118176017A CN118176017A CN202280066732.3A CN202280066732A CN118176017A CN 118176017 A CN118176017 A CN 118176017A CN 202280066732 A CN202280066732 A CN 202280066732A CN 118176017 A CN118176017 A CN 118176017A
- Authority
- CN
- China
- Prior art keywords
- antibody
- amino acid
- seq
- acid sequence
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 206010028980 Neoplasm Diseases 0.000 title abstract description 70
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 259
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 259
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 197
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 197
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 195
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract description 191
- 229960005277 gemcitabine Drugs 0.000 claims abstract description 190
- 108010088751 Albumins Proteins 0.000 claims abstract description 186
- 102000009027 Albumins Human genes 0.000 claims abstract description 186
- 150000003839 salts Chemical class 0.000 claims abstract description 139
- 239000008194 pharmaceutical composition Substances 0.000 claims description 175
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 152
- 238000011282 treatment Methods 0.000 claims description 121
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 119
- 201000002528 pancreatic cancer Diseases 0.000 claims description 119
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 117
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 117
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 60
- 230000027455 binding Effects 0.000 claims description 54
- 239000012634 fragment Substances 0.000 claims description 53
- 229920001184 polypeptide Polymers 0.000 claims description 52
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 52
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 41
- 241000282414 Homo sapiens Species 0.000 claims description 29
- 239000000427 antigen Substances 0.000 claims description 28
- 102000036639 antigens Human genes 0.000 claims description 28
- 108091007433 antigens Proteins 0.000 claims description 28
- 230000001394 metastastic effect Effects 0.000 claims description 27
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 230000000259 anti-tumor effect Effects 0.000 claims description 6
- 230000000306 recurrent effect Effects 0.000 claims description 5
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 3
- 201000011523 endocrine gland cancer Diseases 0.000 claims description 3
- 230000009996 pancreatic endocrine effect Effects 0.000 claims description 3
- 208000012110 pancreatic exocrine neoplasm Diseases 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 58
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 abstract description 29
- 229960001756 oxaliplatin Drugs 0.000 abstract description 29
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract description 28
- 229960002949 fluorouracil Drugs 0.000 abstract description 28
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract description 28
- 229960004768 irinotecan Drugs 0.000 abstract description 28
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 abstract 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 abstract 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 abstract 1
- 235000008191 folinic acid Nutrition 0.000 abstract 1
- 239000011672 folinic acid Substances 0.000 abstract 1
- 229960001691 leucovorin Drugs 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 38
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 38
- 238000002347 injection Methods 0.000 description 31
- 239000007924 injection Substances 0.000 description 31
- 229940090044 injection Drugs 0.000 description 30
- 239000000203 mixture Substances 0.000 description 30
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 27
- 235000008207 calcium folinate Nutrition 0.000 description 27
- 239000011687 calcium folinate Substances 0.000 description 27
- 238000009472 formulation Methods 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 230000003902 lesion Effects 0.000 description 19
- 239000002775 capsule Substances 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 238000001990 intravenous administration Methods 0.000 description 18
- 230000004083 survival effect Effects 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 108010074708 B7-H1 Antigen Proteins 0.000 description 11
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 9
- 239000012931 lyophilized formulation Substances 0.000 description 9
- 238000001959 radiotherapy Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 238000011521 systemic chemotherapy Methods 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 206010061818 Disease progression Diseases 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 description 6
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 230000005750 disease progression Effects 0.000 description 6
- PJZDLZXMGBOJRF-CXOZILEQSA-L folfirinox Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PJZDLZXMGBOJRF-CXOZILEQSA-L 0.000 description 6
- 239000012669 liquid formulation Substances 0.000 description 6
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 description 6
- -1 quinoline derivative tyrosine kinase inhibitor Chemical class 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- 238000011269 treatment regimen Methods 0.000 description 6
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 108010075254 C-Peptide Proteins 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 238000009098 adjuvant therapy Methods 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 4
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000007385 chemical modification Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000011227 neoadjuvant chemotherapy Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- KSMZEXLVHXZPEF-UHFFFAOYSA-N 1-[[4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)C=CN=C2C=C1OCC1(N)CC1 KSMZEXLVHXZPEF-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010061819 Disease recurrence Diseases 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 108091005735 TGF-beta receptors Proteins 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 2
- 206010066901 Treatment failure Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000011226 adjuvant chemotherapy Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229940124618 Anlotinib Drugs 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010067517 Pancreatic neuroendocrine tumour Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940028652 abraxane Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 229940121530 balstilimab Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229950007712 camrelizumab Drugs 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 201000002981 colloid carcinoma of the pancreas Diseases 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940108949 paclitaxel injection Drugs 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 229940125310 socazolimab Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Provided is a combination for treating tumors comprising an anti-PD-L1 antibody-TGF-beta RII fusion protein, gemcitabine and albumin paclitaxel; optionally, an Luoti Ni or a pharmaceutically acceptable salt thereof is also included. Also provided is a combination for treating tumors comprising an anti-PD-L1 antibody-TGF-beta RII fusion protein, folinic acid, fluorouracil, irinotecan, and oxaliplatin; optionally, an Luoti Ni or a pharmaceutically acceptable salt thereof is also included. Also provided are kits for treating tumors comprising the combination. In addition, the application of the combination medicine in preparing a medicine for treating tumors and a method for treating tumors by using the combination medicine are also provided.
Description
The present disclosure belongs to the field of biological medicine, and is especially one kind of combined medicine for treating tumor.
Pancreatic cancer is the most invasive cancer and metastasis has occurred at the beginning of the majority of patients. Metastatic pancreatic cancer prognosis is extremely poor, and even though surgical techniques, drug treatments, and the like for treating pancreatic cancer are continuously improved with the development of technology, improvement of survival rate of pancreatic cancer patients is still very limited, and in the past 45 years (1975-2020), survival rate of pancreatic cancer patients in 5 years is only improved from 3% to 9%.
Currently, there are two first line treatment regimens recommended in many countries around the world, including the guidelines for pancreatic cancer treatment, for metastatic pancreatic cancer that lose surgical value, mainly rely on drug therapy, namely the AG regimen (Gemcitabine) and albumin paclitaxel (Abraxane/nab-paclitaxel) in combination, and the FOLFIRINOX regimen (calcium folinate, fluorouracil, irinotecan and oxaliplatin in combination).
Programmed death ligand 1 (PD-L1) is a ligand of Programmed death molecule 1 (PD-1), highly expressed in various solid malignant tumors, and the expression level is closely related to the clinical manifestation and prognosis of the subject. In the tumor microenvironment, the PD-L1 on the surface of the tumor cells inhibits the activation and proliferation of the T cells through the combination with the PD-1 or CD80 on the surface of the T cells, promotes the effector T cells to enter a failure or non-reaction state, induces the apoptosis of the T cells, stimulates the helper T cells to differentiate into regulatory T cells, and further prevents the T cells from killing the tumor cells. The anti-PD-L1 antibody can prevent the activity of effector T cells in the tumor microenvironment from being inhibited by blocking the interaction of PD-L1, PD-1 and CD80, and enhance the endogenous anti-tumor immune effect. TGF-beta (Transforming growth factor beta) belongs to the TGF-beta superfamily that regulates cell growth and differentiation, promotes tumor invasion and metastasis by mediating SMAD pathways, and simultaneously inhibits activation and differentiation of T cells, improves PD-L1 expression, and further promotes tumor growth. The anti-PD-L1 antibody-TGF beta RII fusion protein can inhibit the TGF-beta signal channel on the basis of inhibiting the PD-L1/PD-1 channel, improve the immune microenvironment and enhance the effect of immunotherapy.
Tyrosine kinases (Tyrosine kinase) are a group of enzymes that catalyze the phosphorylation of protein Tyrosine residues, play an important role in intracellular signal transduction, and are involved in the regulation, signal transmission and development of normal cells, and are also closely related to proliferation, differentiation, migration and apoptosis of tumor cells. Many receptor tyrosine kinases (Receptor tyrosine kinase, RTKs) are involved in tumor formation and can be classified into Epidermal Growth Factor Receptor (EGFR), platelet Derived Growth Factor Receptor (PDGFR), vascular Endothelial Growth Factor Receptor (VEGFR), fibroblast Growth Factor Receptor (FGFR) and the like, depending on the structure of their extracellular regions.
An Luoti Ni (Anlotinib) is a quinoline derivative tyrosine kinase inhibitor, and the quinoline derivative tyrosine kinase inhibitor plays a role in influencing tumor angiogenesis and proliferation signal transduction, and main targets comprise: receptor tyrosine kinases VEGFR1 (FLT 1), VEGFR2 (KDR), VEGFR3 (FLT 4), EGFR, FGFR1-4, pdgfrα and β, and Stem Cell Factor Receptors (SCFR) 7, 8 and 9.
Thus, there is a need for more effective therapeutic agents for clinical use, such as the use of a combination of more than one drug.
Summary of The Invention
In one aspect, the present disclosure provides a pharmaceutical combination comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel; optionally, an Luoti Ni or a pharmaceutically acceptable salt thereof is also included.
In some embodiments, the pharmaceutical combination comprises a pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, a pharmaceutical composition comprising gemcitabine, and a pharmaceutical composition comprising albumin paclitaxel; optionally, a pharmaceutical composition comprising An Luoti Ni or a pharmaceutically acceptable salt thereof is also included.
In some embodiments, the pharmaceutical combination comprises an anti-PD-L1 antibody-tgfbetarii fusion protein in a unit dose of 200-1200mg, gemcitabine in a unit dose of 0.2g and/or 1.0g, and albumin paclitaxel in a unit dose of 100 mg; optionally, the pharmaceutical combination further comprises An Luoti ni or a pharmaceutically acceptable salt thereof in unit doses of 6mg, 8mg, 10mg and/or 12 mg.
In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel may be packaged separately or together. And wherein the anti-PD-L1 antibody-tgfbetarii fusion protein is capable of being packaged in a single or multiple aliquots, the gemcitabine is capable of being packaged in a single or multiple aliquots, and the albumin paclitaxel is capable of being packaged in a single or multiple aliquots.
In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, and An Luoti b, or a pharmaceutically acceptable salt thereof, may be packaged separately or together. And wherein the anti-PD-L1 antibody-tgfbetarii fusion protein is capable of being packaged in one or more aliquots, the gemcitabine is capable of being packaged in one or more aliquots, the albumin paclitaxel is capable of being packaged in one or more aliquots, and the An Luoti ni or pharmaceutically acceptable salt thereof is capable of being packaged in one or more aliquots.
In some embodiments, the pharmaceutical combination is for treating a tumor. In some embodiments, the pharmaceutical combination is for treating pancreatic cancer.
In another aspect, the present disclosure provides a pharmaceutical combination for treating pancreatic cancer comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel; optionally, an Luoti Ni or a pharmaceutically acceptable salt thereof is also included.
In another aspect, the present disclosure also provides a method of treating pancreatic cancer in a subject comprising administering to the subject an effective amount of a pharmaceutical combination of the present disclosure. In addition, the present disclosure also provides the use of the pharmaceutical combination of the present disclosure in the manufacture of a medicament for the treatment of pancreatic cancer. Or the disclosure also provides the use of an anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel, optionally, also including An Luoti ni or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating pancreatic cancer.
In some embodiments, the pharmaceutical combination is a fixed combination. In some embodiments, the fixed combination is in the form of a solid pharmaceutical composition or in the form of a liquid pharmaceutical composition.
In some embodiments, the pharmaceutical combination is a non-fixed combination. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel in the non-fixed combination are each in the form of a pharmaceutical composition. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, and An Luoti ni, or a pharmaceutically acceptable salt thereof, in the non-fixed combination are each in the form of a pharmaceutical composition.
In some embodiments, the non-fixed combination, the pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein is a liquid pharmaceutical composition. In some embodiments, the liquid pharmaceutical composition is an injection.
In some embodiments, the non-fixed combination, the gemcitabine-comprising pharmaceutical composition is a solid pharmaceutical composition.
In some embodiments, the non-fixed combination, the pharmaceutical composition comprising albumin paclitaxel is a solid pharmaceutical composition.
In some embodiments, the pharmaceutical composition comprising An Luoti n or a pharmaceutically acceptable salt thereof in the non-fixed combination is a solid pharmaceutical composition.
In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel are each in the form of a pharmaceutical composition, which may be administered simultaneously, sequentially, and/or alternately. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, and An Luoti b, or a pharmaceutically acceptable salt thereof, are each in the form of a pharmaceutical composition, which may be administered simultaneously, sequentially, and/or alternately.
In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein is administered once every 1 week, every 2 weeks, every 3 weeks, or every 4 weeks. In some embodiments, the anti-PD-L1 antibody-TGF-beta RII fusion protein is administered at a dose of 600-2400mg, 1200-1800mg, or 1800-2400mg at a time.
In some embodiments, the gemcitabine is administered in a dosage regimen of 500-1000mg/m 2 gemcitabine once a week for 2 weeks, and for 1 week on a continuous basis.
In some embodiments, the albumin paclitaxel is administered in a dose of 75-125mg/m 2 albumin paclitaxel once a week, a regimen of 2 weeks continuous, and 1 week off.
In some embodiments, the An Luoti ni, or pharmaceutically acceptable salt thereof, is administered in a dose of 6mg, 8mg, 10mg, or 12mg An Luoti ni once daily, a regimen of 2 weeks consecutive, 1 week off.
In another aspect, the present disclosure provides a kit for treating pancreatic cancer comprising a pharmaceutical combination of the present disclosure. In some embodiments, the kit comprises an anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel; optionally, an Luoti Ni or a pharmaceutically acceptable salt thereof is also included.
In another aspect, the present disclosure also provides a pharmaceutical combination comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, calcium folinate, fluorouracil, irinotecan, and oxaliplatin; optionally, an Luoti Ni or a pharmaceutically acceptable salt thereof is also included. In addition, the present disclosure provides a pharmaceutical combination for treating pancreatic cancer comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, calcium folinate, fluorouracil, irinotecan, and oxaliplatin; optionally, an Luoti Ni or a pharmaceutically acceptable salt thereof is also included. In addition, the disclosure also provides the use of an anti-PD-L1 antibody-tgfbetarii fusion protein, calcium folinate, fluorouracil, irinotecan, and oxaliplatin, optionally, also including An Luoti ni or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of pancreatic cancer tumors.
Detailed Description
The present disclosure provides pharmaceutical combinations comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel; optionally, an Luoti Ni or a pharmaceutically acceptable salt thereof is also included. Or the present disclosure also provides a pharmaceutical combination comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, calcium folinate, fluorouracil, irinotecan, and oxaliplatin; optionally, an Luoti Ni or a pharmaceutically acceptable salt thereof is also included. In some embodiments, the pharmaceutical combination is for treating a tumor.
The present disclosure also provides the use of the pharmaceutical combination of the present disclosure in the manufacture of a medicament for the treatment of a tumor. The present disclosure also provides for the use of the pharmaceutical combinations of the present disclosure for the treatment of tumors. The present disclosure also provides a method of treating a tumor comprising administering to a subject an effective amount of a pharmaceutical combination of the present disclosure.
The present disclosure also provides kits for treating tumors comprising the pharmaceutical combinations of the present disclosure. In some embodiments, the kit further comprises instructions for treating a tumor with the pharmaceutical combination of the present disclosure.
In addition, the present disclosure also provides anti-PD-L1 antibody-TGF-beta RII fusion proteins for use in the treatment of tumors. The disclosure also provides for the use of an anti-PD-L1 antibody-tgfbetarii fusion protein in the manufacture of a medicament for treating a tumor. The disclosure also provides for the use of an anti-PD-L1 antibody-tgfbetarii fusion protein for treating a tumor. The present disclosure also provides methods of treating a tumor comprising administering to a subject an effective amount of an anti-PD-L1 antibody-tgfbetarii fusion protein of the present disclosure.
In some embodiments, the tumor is pancreatic cancer.
Pharmaceutical combination
In one aspect, the present disclosure provides a pharmaceutical combination comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel. Optionally, the pharmaceutical combination further comprises An Luoti ni or a pharmaceutically acceptable salt thereof.
In some embodiments, the pharmaceutical combination comprises a pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, a pharmaceutical composition comprising gemcitabine, and a pharmaceutical composition comprising albumin paclitaxel. Optionally, the pharmaceutical combination further comprises a pharmaceutical composition comprising An Luoti ni or a pharmaceutically acceptable salt thereof.
In some embodiments, the pharmaceutical combination is packaged in the same kit, which further includes instructions for the combined use of an anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel to treat tumors. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel in the pharmaceutical combination are packaged separately in separate kits, which further include instructions for the combined use of the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel to treat the tumor. In other embodiments, the pharmaceutical combination is packaged in the same kit, which further comprises instructions for the combined use of an anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, and An Luoti ni, or a pharmaceutically acceptable salt thereof, to treat a tumor. In still other embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, an Luoti ni, or a pharmaceutically acceptable salt thereof in the pharmaceutical combination are separately packaged in separate kits that further include instructions for the combined use of the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, an Luoti ni, or a pharmaceutically acceptable salt thereof, to treat a tumor. In some embodiments, the tumor is pancreatic cancer.
In some embodiments, the pharmaceutical combination comprises an anti-PD-L1 antibody-TGF-beta RII fusion protein in a unit dose of 200-1200mg or 200-600mg, gemcitabine in a unit dose of 0.2g and/or 1.0g, and albumin paclitaxel in a unit dose of 100 mg. Optionally, the pharmaceutical combination further comprises An Luoti ni or a pharmaceutically acceptable salt thereof in unit doses of 6mg, 8mg, 10mg and/or 12 mg.
In some embodiments, the pharmaceutical combination comprises an anti-PD-L1 antibody-tgfbetarii fusion protein in a unit dose of about 200mg, about 250mg, about 300mg, about 350mg, about 400mg, about 450mg, about 500mg, about 550mg, about 600mg, about 700mg, about 800mg, about 900mg, about 1000mg, about 1100mg, and/or about 1200mg, gemcitabine in a unit dose of 0.2g and/or 1.0g, and paclitaxel in an albumin in unit dose of 100 mg. Optionally, the pharmaceutical combination further comprises An Luoti ni or a pharmaceutically acceptable salt thereof in unit doses of 6mg, 8mg, 10mg and/or 12 mg.
In some embodiments, the pharmaceutical combination comprises an anti-PD-L1 antibody-tgfbetarii fusion protein in a unit dose of about 200mg, about 400mg, and/or about 600mg, gemcitabine in a unit dose of 0.2g and/or 1.0g, and albumin paclitaxel in a unit dose of 100 mg. Optionally, the pharmaceutical combination further comprises An Luoti ni or a pharmaceutically acceptable salt thereof in unit dose of 8mg, 10mg and/or 12 mg.
In some embodiments, the pharmaceutical combination comprises a pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein in a unit dose of 200-1200mg or 200-600mg of an anti-PD-L1 antibody-tgfbetarii fusion protein, a pharmaceutical composition comprising gemcitabine in a unit dose of 0.2g and/or 1.0g of gemcitabine, and a pharmaceutical composition comprising albumin paclitaxel in a unit dose of 100mg of albumin paclitaxel; wherein the pharmaceutical composition containing the anti-PD-L1 antibody-TGF-beta RII fusion protein is in single dose or multiple doses. Optionally, the pharmaceutical combination further comprises a pharmaceutical composition comprising An Luoti ni or a pharmaceutically acceptable salt thereof in unit dose of 6mg, 8mg, 10mg and/or 12mg An Luoti ni. In some embodiments, the pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein is a multi-dose.
In some embodiments, the pharmaceutical combination comprises a unit dose of about 200mg, about 250mg, about 300mg, about 350mg, about 400mg, about 450mg, about 500mg, about 550mg, about 600mg, about 700mg, about 800mg, about 900mg, about 1000mg, about 1100mg, and/or about 1200mg of an anti-PD-L1 antibody-tgfbetarii fusion protein-containing pharmaceutical composition, a unit dose of 0.2g and/or 1.0g of gemcitabine-containing pharmaceutical composition, and a unit dose of 100mg of albumin-paclitaxel-containing pharmaceutical composition; wherein the pharmaceutical composition containing the anti-PD-L1 antibody-TGF-beta RII fusion protein is in single dose or multiple doses. Optionally, the pharmaceutical combination further comprises a pharmaceutical composition comprising An Luoti ni or a pharmaceutically acceptable salt thereof in unit dose of 6mg, 8mg, 10mg and/or 12mg An Luoti ni. In some embodiments, the pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein is a multi-dose.
In some embodiments, the pharmaceutical combination comprises a pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein in a unit dose of about 200mg, about 400mg, and/or about 600mg of the anti-PD-L1 antibody-tgfbetarii fusion protein, a pharmaceutical composition comprising gemcitabine in a unit dose of 0.2g and/or 1.0g of gemcitabine, and a pharmaceutical composition comprising albumin paclitaxel in a unit dose of 100mg of albumin paclitaxel; wherein the pharmaceutical composition containing the anti-PD-L1 antibody-TGF-beta RII fusion protein is in single dose or multiple doses. Optionally, the pharmaceutical combination further comprises a pharmaceutical composition comprising An Luoti ni or a pharmaceutically acceptable salt thereof in unit dose of 8mg, 10mg and/or 12mg An Luoti ni. In some embodiments, the pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein is a multi-dose.
In some embodiments, the pharmaceutical combination comprises 600-2400mg, 1200-1800mg, or 1800-2400mg of an anti-PD-L1 antibody-TGF-beta RII fusion protein, 100-3000mg/m 2、200-2000mg/m 2、500-1500mg/m 2, or 500-1000mg/m 2 of gemcitabine, and 10-500mg/m 2、30-300mg/m 2、100-200mg/m 2, or 75-125mg/m 2 of albumin paclitaxel. Optionally, the pharmaceutical combination further comprises 8mg, 10mg and/or 12mg An Luoti mg of An Luoti ni or a pharmaceutically acceptable salt thereof.
In some embodiments, the pharmaceutical combination comprises about 600mg, about 700mg, about 800mg, about 900mg, about 1000mg, about 1100mg, about 1200mg, about 1300mg, about 1400mg, about 1500mg, about 1600mg, about 1700mg, about 1800mg, about 1900mg, about 2000mg, about 2100mg, about 2200mg, about 2300mg, and/or about 2400mg of an anti-PD-L1 antibody-tgfbetarii fusion protein, 500-1000mg/m 2 of gemcitabine, and 75-125mg/m 2 of albumin paclitaxel. Optionally, the pharmaceutical combination further comprises 8mg, 10mg and/or 12mg An Luoti mg of An Luoti ni or a pharmaceutically acceptable salt thereof.
In some embodiments, the pharmaceutical combination comprises about 600mg, about 1200mg, about 1800mg, and/or about 2400mg of an anti-PD-L1 antibody-tgfbetarii fusion protein, 500-1000mg/m 2 of gemcitabine, and 75-125mg/m 2 of albumin paclitaxel. Optionally, the pharmaceutical combination further comprises 8mg, 10mg and/or 12mg An Luoti mg of An Luoti ni or a pharmaceutically acceptable salt thereof.
In some embodiments, the pharmaceutical combination comprises about 1200mg and/or about 1800mg of an anti-PD-L1 antibody-tgfbetarii fusion protein, 1000mg/m 2 of gemcitabine, and 125mg/m 2 of albumin paclitaxel. Optionally, the pharmaceutical combination further comprises 8mg An Luoti ni or a pharmaceutically acceptable salt thereof.
In some embodiments, the amount of anti-PD-L1 antibody-tgfbetarii fusion protein in the pharmaceutical combination is one daily dose. In some embodiments, the amount of anti-PD-L1 antibody-tgfbetarii fusion protein in the pharmaceutical combination is a daily dose.
In some embodiments, the amount of anti-PD-L1 antibody-tgfbetarii fusion protein in the pharmaceutical combination is a uniform dose.
In some embodiments, the amount of gemcitabine in the pharmaceutical combination is one daily dose. In some embodiments, the amount of gemcitabine in the pharmaceutical combination is one daily dose.
In some embodiments, the amount of albumin paclitaxel in the pharmaceutical combination is one daily dose. In some embodiments, the amount of albumin paclitaxel in the pharmaceutical combination is a once daily dose.
In some embodiments, the amount of An Luoti n or a pharmaceutically acceptable salt thereof in the pharmaceutical combination is one daily dose. In some embodiments, the amount of An Luoti n or a pharmaceutically acceptable salt thereof in the pharmaceutical combination is one daily dose.
In some embodiments, the pharmaceutical combination is suitable for administration within a single treatment cycle, comprising 600-2400mg, 1200-1800mg, or 1800-2400mg of an anti-PD-L1 antibody-TGF-beta RII fusion protein, 200-6000mg/m 2、400-4000mg/m 2、1000-3000mg/m 2, or 1000-2000mg/m 2 of gemcitabine, and 20-1000mg/m 2、60-600mg/m 2、200-400mg/m 2, or 150-250mg/m 2 of albumin paclitaxel. Optionally, the pharmaceutical combination further comprises 84-168mg An Luoti ni or a pharmaceutically acceptable salt thereof.
In some embodiments, the pharmaceutical combination is suitable for administration within a single treatment cycle, comprising about 600mg, about 700mg, about 800mg, about 900mg, about 1000mg, about 1100mg, about 1200mg, about 1300mg, about 1400mg, about 1500mg, about 1600mg, about 1700mg, about 1800mg, about 1900mg, about 2000mg, about 2100mg, about 2200mg, about 2300mg and/or about 2400mg of an anti-PD-L1 antibody-tgfbetarii fusion protein, 1000-2000mg/m 2 of gemcitabine, and 150-250mg/m 2 of albumin paclitaxel. Optionally, the pharmaceutical combination further comprises 84-168mg An Luoti ni or a pharmaceutically acceptable salt thereof.
In some embodiments, the pharmaceutical combination is suitable for administration within a single treatment cycle, comprising about 600mg, about 1200mg, about 1800mg, and/or about 2400mg of an anti-PD-L1 antibody-tgfbetarii fusion protein, 1000-2000mg/m 2 of gemcitabine, and 150-250mg/m 2 of albumin paclitaxel. Optionally, the pharmaceutical combination further comprises 84-168mg An Luoti ni or a pharmaceutically acceptable salt thereof.
In some embodiments, the pharmaceutical combination is suitable for administration within a single treatment cycle, comprising about 1200mg and/or about 1800mg of an anti-PD-L1 antibody-tgfbetarii fusion protein, 2000mg/m 2 of gemcitabine, and 250mg/m 2 of albumin paclitaxel. Optionally, the pharmaceutical combination further comprises 112mg An Luoti ni or a pharmaceutically acceptable salt thereof.
In some embodiments, the pharmaceutical combination is suitable for administration within a single treatment cycle, including a pharmaceutical composition comprising 600-2400mg, 1200-1800mg, or 1800-2400mg of an anti-PD-L1 antibody-tgfbetarii fusion protein, a pharmaceutical composition comprising 200-6000mg/m 2、400-4000mg/m 2、1000-3000mg/m 2, or 1000-2000mg/m 2 gemcitabine, and a pharmaceutical composition comprising 20-1000mg/m 2、60-600mg/m 2、200-400mg/m 2, or 150-250mg/m 2 albumin paclitaxel; wherein the pharmaceutical composition containing the anti-PD-L1 antibody-TGF-beta RII fusion protein is in single dose or multiple doses. Optionally, the pharmaceutical combination further comprises a pharmaceutical composition comprising 84-168mg An Luoti ni or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein is a multi-dose.
In some embodiments, the pharmaceutical combination is suitable for administration within a single treatment cycle and includes a pharmaceutical composition comprising about 600mg, about 700mg, about 800mg, about 900mg, about 1000mg, about 1100mg, about 1200mg, about 1300mg, about 1400mg, about 1500mg, about 1600mg, about 1700mg, about 1800mg, about 1900mg, about 2000mg, about 2100mg, about 2200mg, about 2300mg, and/or about 2400mg of an anti-PD-L1 antibody-tgfbetarii fusion protein, a pharmaceutical composition comprising 1000-2000mg/m 2 gemcitabine, and a pharmaceutical composition comprising 150-250mg/m 2 albumin paclitaxel; wherein the pharmaceutical composition containing the anti-PD-L1 antibody-TGF-beta RII fusion protein is in single dose or multiple doses. Optionally, the pharmaceutical combination further comprises a pharmaceutical composition comprising 84-168mg An Luoti ni or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein is a multi-dose.
In some embodiments, the pharmaceutical combination is suitable for administration within a single treatment cycle, including a pharmaceutical composition comprising about 600mg, about 1200mg, about 1800mg, and/or about 2400mg of an anti-PD-L1 antibody-tgfbetarii fusion protein, a pharmaceutical composition comprising 1000-2000mg/m 2 gemcitabine, and a pharmaceutical composition comprising 150-250mg/m 2 albumin paclitaxel; wherein the pharmaceutical composition containing the anti-PD-L1 antibody-TGF-beta RII fusion protein is in single dose or multiple doses. Optionally, the pharmaceutical combination further comprises a pharmaceutical composition comprising 84-168mg An Luoti ni or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein is a multi-dose.
In some embodiments, the pharmaceutical combination is suitable for administration within a single treatment cycle, including a pharmaceutical composition comprising about 1200mg and/or about 1800mg of an anti-PD-L1 antibody-tgfbetarii fusion protein, a pharmaceutical composition comprising 2000mg/m 2 gemcitabine, and a pharmaceutical composition comprising 250mg/m 2 albumin paclitaxel; wherein the pharmaceutical composition containing the anti-PD-L1 antibody-TGF-beta RII fusion protein is in single dose or multiple doses. Optionally, the pharmaceutical combination further comprises a pharmaceutical composition comprising 112mg An Luoti of a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein is a multi-dose.
In some embodiments, the pharmaceutical combination wherein the mass ratio of the anti-PD-L1 antibody-TGF-beta RII fusion protein to gemcitabine is (0.1-10): 1, (0.125-2): 1, (0.125-1.5): 1 or (0.25-1.5): 1, and the mass ratio of the anti-PD-L1 antibody-TGF-beta RII fusion protein to albumin paclitaxel is (0.1-30): 1, (1-15): 1, (2-15): 1 or (2-10): 1; wherein the anti-PD-L1 antibody-TGF-beta RII fusion protein, gemcitabine, and albumin paclitaxel may be packaged separately or together. And wherein the anti-PD-L1 antibody-tgfbetarii fusion protein can be packaged in a single or multiple aliquots (e.g., 2, 3,4, 5, 6, 7, 8,9, 10, 12 or more aliquots); gemcitabine may be packaged in single or multiple aliquots; albumin paclitaxel can be packaged in single or multiple aliquots.
In still other embodiments, the pharmaceutical combination has a mass ratio of (0.1-10): 1, (0.125-2): 1, (0.125-1.5): 1 or (0.25-1.5): 1, the anti-PD-L1 antibody-tgfbetarii fusion protein and albumin paclitaxel of (0.1-30): 1, (1-15): 1, (2-15): 1 or (2-10): 1, the anti-PD-L1 antibody-tgfbetarii fusion protein and An Luoti or a pharmaceutically acceptable salt thereof of (3.5-29.0): 1, (7.1-21.5): 1, (7.1-14.5): 1, (10.5-21.5): 1, 50:7 or 75:7; wherein the anti-PD-L1 antibody-TGF-beta RII fusion protein, gemcitabine, albumin paclitaxel, an Luoti or a pharmaceutically acceptable salt thereof may be packaged separately or together. And wherein the anti-PD-L1 antibody-tgfbetarii fusion protein can be packaged in a single or multiple aliquots (e.g., 2,3, 4,5, 6, 7, 8, 9, 10, 12 or more aliquots); gemcitabine may be packaged in single or multiple aliquots; albumin paclitaxel can be packaged in single or multiple aliquots; an Luoti Ni or a pharmaceutically acceptable salt thereof can be packaged in single or multiple aliquots (e.g., 7, 14, 28 or more aliquots).
In some embodiments, the pharmaceutical combination comprises a pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, a pharmaceutical composition comprising gemcitabine, and a pharmaceutical composition comprising albumin paclitaxel, wherein the pharmaceutical composition comprising anti-PD-L1 antibody-tgfbetarii fusion protein is prepared to be suitable for administration of a single dose or multiple doses of 600-2400mg, 1200-1800mg, or 1800-2400mg of the anti-PD-L1 antibody-tgfbetarii fusion protein to a patient at the first administration, and the pharmaceutical composition comprising gemcitabine is prepared to be suitable for administration of a single dose or multiple doses of 100-3000mg/m 2、200-2000mg/m 2、500-1500mg/m 2, or 500-1000mg/m 2 gemcitabine to a patient at the second administration of 10-500mg/m 2、30-300mg/m 2、100-200mg/m 2, or 75-125mg/m 2 albumin paclitaxel to a patient at the first administration.
In some embodiments, the pharmaceutical combination comprises a pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, a pharmaceutical composition comprising gemcitabine, and a pharmaceutical composition comprising albumin paclitaxel, wherein the pharmaceutical composition comprising gemcitabine is prepared to be suitable for administration of a single dose or multiple doses of about 600mg, about 700mg, about 800mg, about 900mg, about 1000mg, about 1100mg, about 1200mg, about 1300mg, about 1400mg, about 1500mg, about 1600mg, about 1700mg, about 1800mg, about 1900mg, about 2000mg, about 2100mg, about 2200mg, about 2300mg, or about 2400mg of the anti-PD-L1 antibody-tgfbetarii fusion protein to a patient when the pharmaceutical composition comprising gemcitabine is prepared to be suitable for continuous 2 weeks, a single dose or multiple doses of 500-1000mg/m 2 gemcitabine to the patient, and the pharmaceutical composition comprising albumin paclitaxel is prepared to be suitable for continuous 2 weeks, a single dose or multiple doses of 2 mg/m paclitaxel to the patient when the pharmaceutical composition comprises gemcitabine.
In some embodiments, the pharmaceutical combination comprises a pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, a pharmaceutical composition comprising gemcitabine, and a pharmaceutical composition comprising albumin paclitaxel, wherein the pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein is prepared to be suitable for administration to a patient at a single dose or multiple doses of about 600mg, about 1200mg, about 1800mg, or about 2400mg of the anti-PD-L1 antibody-tgfbetarii fusion protein at the first administration, the pharmaceutical composition comprising gemcitabine is prepared to be suitable for administration to a patient for a single dose or multiple doses of 500-1000mg/m 2 gemcitabine for a continuous 2 weeks, and the pharmaceutical composition comprising albumin paclitaxel is prepared to be suitable for administration to a patient for a single dose or multiple doses of 75-125mg/m 2 albumin paclitaxel for a continuous 2 weeks.
In some embodiments, the pharmaceutical combination comprises a pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, a pharmaceutical composition comprising gemcitabine, and a pharmaceutical composition comprising albumin paclitaxel, wherein the pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein is prepared to be suitable for administration to a patient of about 1200mg or about 1800mg of the single dose or multiple doses of the anti-PD-L1 antibody-tgfbetarii fusion protein when administered for the first time, the pharmaceutical composition comprising gemcitabine is prepared to be suitable for administration of 1000mg/m 2 gemcitabine to a patient for 2 consecutive weeks, and the pharmaceutical composition comprising albumin paclitaxel is prepared to be suitable for administration of 125mg/m 2 of albumin paclitaxel to a patient for 2 consecutive weeks.
In other embodiments, the pharmaceutical composition comprising An Luoti n or a pharmaceutically acceptable salt thereof is prepared as a single dose suitable for administration to a patient of 6-12mg An Luoti n daily for 14 consecutive days. More specifically, the pharmaceutical composition containing An Luoti ni or a pharmaceutically acceptable salt thereof is prepared as a single dose suitable for administration of 6mg, 8mg, 10mg or 12mg An Luoti ni to a patient daily for 14 consecutive days. More specifically, the pharmaceutical composition containing An Luoti n or a pharmaceutically acceptable salt thereof is prepared as a single dose of 8mg An Luoti n administered daily to a patient for 14 consecutive days.
In another aspect, the present disclosure also provides the use of a pharmaceutical combination comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine and albumin paclitaxel in the manufacture of a medicament for the treatment of a tumor. The present disclosure also provides for the use of a pharmaceutical combination comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine and albumin paclitaxel for the treatment of tumors. The present disclosure also provides a method of treating a tumor in a subject comprising administering to the subject an effective amount of a pharmaceutical combination comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel. In some embodiments, the tumor is pancreatic cancer.
Or the disclosure also provides the use of a pharmaceutical combination comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, and An Luoti ni, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a tumor. The present disclosure also provides for the use of a pharmaceutical combination comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, and An Luoti ni, or a pharmaceutically acceptable salt thereof, to treat a tumor. The disclosure also provides methods of treating a tumor in a subject comprising administering to the subject an effective amount of a pharmaceutical combination comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, and An Luoti ni, or a pharmaceutically acceptable salt thereof. In some embodiments, the tumor is pancreatic cancer.
In another aspect, the present disclosure provides a kit for treating a tumor, the kit comprising a pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, a pharmaceutical composition comprising gemcitabine and a pharmaceutical composition comprising albumin paclitaxel, and instructions for using the pharmaceutical composition comprising the anti-PD-L1 antibody-tgfbetarii fusion protein, the pharmaceutical composition comprising gemcitabine and the pharmaceutical composition comprising albumin paclitaxel in combination to treat the tumor. In some embodiments, the tumor is pancreatic cancer.
Or the present disclosure provides a kit for treating a tumor comprising a pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, a pharmaceutical composition comprising gemcitabine, a pharmaceutical composition comprising albumin paclitaxel, and a pharmaceutical composition comprising An Luoti ni or a pharmaceutically acceptable salt thereof, and instructions for using the pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, the pharmaceutical composition comprising gemcitabine, the pharmaceutical composition comprising albumin paclitaxel, and the pharmaceutical composition comprising An Luoti ni or a pharmaceutically acceptable salt thereof in combination to treat a tumor. In some embodiments, the tumor is pancreatic cancer.
In addition, the present disclosure also provides pharmaceutical combinations comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, calcium folinate, fluorouracil, irinotecan, and oxaliplatin. Optionally, the pharmaceutical combination further comprises An Luoti ni or a pharmaceutically acceptable salt thereof.
In some embodiments, the pharmaceutical combination comprises a pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, a pharmaceutical composition comprising calcium folinate, a pharmaceutical composition comprising fluorouracil, a pharmaceutical composition comprising irinotecan, and a pharmaceutical composition comprising oxaliplatin. Optionally, the pharmaceutical combination further comprises a pharmaceutical composition comprising An Luoti ni or a pharmaceutically acceptable salt thereof.
The present disclosure also provides the use of a pharmaceutical combination comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, calcium folinate, fluorouracil, irinotecan and oxaliplatin in the manufacture of a medicament for the treatment of a tumor. The present disclosure also provides for the use of a pharmaceutical combination comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, calcium folinate, fluorouracil, irinotecan, and oxaliplatin for the treatment of tumors. The present disclosure also provides a method of treating a tumor in a subject comprising administering to the subject an effective amount of a pharmaceutical combination comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, calcium folinate, fluorouracil, irinotecan, and oxaliplatin. In some embodiments, the tumor is pancreatic cancer.
Or the disclosure also provides the use of a pharmaceutical combination comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, calcium folinate, fluorouracil, irinotecan, oxaliplatin and An Luoti ni, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a tumor. The present disclosure also provides for the use of a pharmaceutical combination comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, calcium folinate, fluorouracil, irinotecan, oxaliplatin and An Luoti ni, or a pharmaceutically acceptable salt thereof, for the treatment of a tumor. The present disclosure also provides a method of treating a tumor in a subject comprising administering to the subject an effective amount of a pharmaceutical combination comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, calcium folinate, fluorouracil, irinotecan, oxaliplatin, and An Luoti ni or a pharmaceutically acceptable salt thereof. In some embodiments, the tumor is pancreatic cancer.
The present disclosure also provides kits for treating tumors comprising a pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, a pharmaceutical composition comprising calcium folinate, a pharmaceutical composition comprising fluorouracil, a pharmaceutical composition comprising irinotecan, and a pharmaceutical composition comprising oxaliplatin. In some embodiments, the kit further comprises a pharmaceutical composition comprising An Luoti ni or a pharmaceutically acceptable salt thereof. In some embodiments, the tumor is pancreatic cancer.
Drug combination dosing/treatment regimen
In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel are each in the form of a pharmaceutical composition for simultaneous, sequential, and/or alternative administration. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel are each administered sequentially in the form of a pharmaceutical composition for use or method of treatment as described above. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel are each administered alternately in the form of a pharmaceutical composition for use or method of treatment as described above. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel are each in the form of a pharmaceutical composition and are each administered in a separate administration. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel are administered separately on the same or different dosing schedules. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel are administered separately in different dosing regimens for the above uses or methods of treatment.
In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, and An Luoti b, or a pharmaceutically acceptable salt thereof, are each in the form of a pharmaceutical composition, which may be administered simultaneously, sequentially, and/or alternately. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, and An Luoti b, or a pharmaceutically acceptable salt thereof, are each administered sequentially in the form of a pharmaceutical composition for use or method of treatment as described above. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, and An Luoti b, or a pharmaceutically acceptable salt thereof, are each in the form of a pharmaceutical composition for alternate administration. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, and An Luoti b, or a pharmaceutically acceptable salt thereof, are each in the form of a pharmaceutical composition and are each administered in a separate administration. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, and An Luoti b, or a pharmaceutically acceptable salt thereof, are administered separately on the same or different dosing schedules. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, and An Luoti b, or a pharmaceutically acceptable salt thereof, are administered separately in different dosing regimens.
In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein is administered weekly (q 1 w), every 2 weeks (q 2 w), every 3 weeks (q 3 w), or every 4 weeks (q 4 w) in the above uses or methods of treatment. In a specific embodiment, the anti-PD-L1 antibody-TGF-beta RII fusion protein is administered once every 3 weeks. In some embodiments, the anti-PD-L1 antibody-TGF-beta RII fusion protein is administered at a dose of 600-2400mg, 1200-1800mg, or 1800-2400mg at a time. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein is administered at a dose of about 600mg, about 700mg, about 800mg, about 900mg, about 1000mg, about 1100mg, about 1200mg, about 1300mg, about 1400mg, about 1500mg, about 1600mg, about 1700mg, about 1800mg, about 1900mg, about 2000mg, about 2100mg, about 2200mg, about 2300mg, or about 2400mg at a time. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein is administered at a dose of about 600mg, about 1200mg, about 1800mg, or about 2400mg at a time. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein is administered at a dose of about 1200mg at a time. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein is administered at a dose of about 1800mg at a time.
In some embodiments, the above-described use or method of treatment, the gemcitabine is administered once a week. In some embodiments, the above uses or methods of treatment, the gemcitabine is administered at a dose of 100-3000mg/m 2、200-2000mg/m 2、500-1500mg/m 2 or 500-1000mg/m 2 at a time. In some embodiments, the above uses or methods of treatment, the gemcitabine is administered at a dose of 500mg/m 2、750mg/m 2 or 1000mg/m 2 at a time. In some embodiments, in the above uses or methods of treatment, the gemcitabine is administered in a dosage of 500-1000mg/m 2 gemcitabine once a week, 2 weeks of continuous dosing, 1 week of dosing regimen. In some embodiments, in the above uses or methods of treatment, the gemcitabine is administered in a dose of 500mg/m 2、750mg/m 2 or 1000mg/m 2 gemcitabine once a week, a2 week continuous regimen, a 1 week off regimen. In some embodiments, in the above uses or methods of treatment, the gemcitabine is administered in a 1000mg/m 2 gemcitabine dose once a week, 2 weeks continuous, 1 week off regimen.
In some embodiments, the albumin paclitaxel is administered once a week in the above uses or methods of treatment. In some embodiments, the albumin paclitaxel is administered at a dose of 10-500mg/m 2、30-300mg/m 2、100-200mg/m 2 or 75-125mg/m 2 at a time in the above uses or methods of treatment. In some embodiments, the albumin paclitaxel is administered at a dose of 75mg/m 2、100mg/m 2 or 125mg/m 2 at a time in the above uses or methods of treatment. In some embodiments, the albumin paclitaxel is administered in a dose of 75-125mg/m 2 albumin paclitaxel once a week, a regimen of 2 weeks continuous, and 1 week off. In some embodiments, in the above uses or methods of treatment, the albumin paclitaxel is administered in a dose of 75mg/m 2、100mg/m 2 or 125mg/m 2 albumin paclitaxel once a week, a2 week continuous regimen, a 1 week off regimen. In some embodiments, in the above uses or methods of treatment, the albumin paclitaxel is administered in a dose of 125mg/m 2 albumin paclitaxel once a week, a regimen of 2 weeks continuous administration, and 1 week withdrawal.
In some embodiments, in the above uses or methods of treatment, the An Luoti ni or pharmaceutically acceptable salt thereof is administered in a dose of 6-12mg An Luoti ni once daily, a regimen of 2 weeks of continuous administration, and 1 week of discontinuation. In some embodiments, in the above uses or methods of treatment, the An Luoti ni or pharmaceutically acceptable salt thereof is administered in a dose of 6mg, 8mg, 10mg, or 12mg An Luoti ni once daily, a regimen of 2 weeks continuous, 1 week off. In some embodiments, in the above uses or methods of treatment, the An Luoti ni or pharmaceutically acceptable salt thereof is administered in a dose of 8mg An Luoti ni once daily, a regimen of 2 weeks of continuous administration, and 1 week of discontinuation.
In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel each have the same or different treatment cycles. In some specific embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel have the same treatment cycle, e.g., one treatment cycle every 1 week, every 2 weeks, every 3 weeks, or every 4 weeks.
In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, and An Luoti b, or pharmaceutically acceptable salts thereof, each have the same or different treatment cycles. In some specific embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, an Luoti, or a pharmaceutically acceptable salt thereof, has the same treatment cycle, e.g., one treatment cycle every 1 week, every 2 weeks, every 3 weeks, or every 4 weeks.
In some embodiments, the above use or method of treatment is one treatment cycle every 21 days, the anti-PD-L1 antibody-tgfbetarii fusion protein is administered in each cycle, gemcitabine is administered at week 1 and week 2 of each cycle, and albumin paclitaxel is administered at weeks 1 and 2 of each cycle, respectively. In some embodiments, the above use or method of treatment is one treatment cycle every 21 days, the anti-PD-L1 antibody-tgfbetarii fusion protein is administered once per cycle, gemcitabine is administered once per week 1 and 2 of each cycle, and albumin paclitaxel is administered once per week 1 and 2 of each cycle. In some embodiments, the above use or method of treatment is one treatment cycle every 21 days, the anti-PD-L1 antibody-tgfbetarii fusion protein is administered on day 1 of each cycle, gemcitabine is administered on days 1 and 8 of each cycle, and albumin paclitaxel is administered on days 1 and 8 of each cycle, respectively. In a specific embodiment, the above use or method of treatment is one treatment cycle every 21 days, the anti-PD-L1 antibody-TGF-beta RII fusion protein is administered once on day 1 of each cycle, gemcitabine is administered once on days 1 and 8 of each cycle, and albumin paclitaxel is administered once on days 1 and 8 of each cycle, respectively.
In some embodiments, the above use or method of treatment is one treatment cycle every 21 days, the anti-PD-L1 antibody-tgfbetarii fusion protein is administered every cycle, gemcitabine is administered at week 1 and week 2 of each cycle, albumin paclitaxel is administered at week 1 and week 2 of each cycle, and An Luoti or a pharmaceutically acceptable salt thereof is administered daily on days 1-14 of each cycle. In some embodiments, the above use or method of treatment is one treatment cycle every 21 days, the anti-PD-L1 antibody-tgfbetarii fusion protein is administered once per cycle, gemcitabine is administered once per week 1 and 2 of each cycle, albumin paclitaxel is administered once per week 1 and 2 of each cycle, and An Luoti ni or a pharmaceutically acceptable salt thereof is administered once per day on days 1-14 of each cycle. In some embodiments, the above use or method of treatment is one treatment cycle every 21 days, the anti-PD-L1 antibody-tgfbetarii fusion protein is administered on day 1 of each cycle, gemcitabine is administered on days 1 and 8 of each cycle, respectively, albumin paclitaxel is administered on days 1 and 8 of each cycle, and An Luoti of each cycle, or a pharmaceutically acceptable salt thereof, is administered daily on days 1-14 of each cycle. In a specific embodiment, the above use or method of treatment is one treatment cycle every 21 days, the anti-PD-L1 antibody-TGF-beta RII fusion protein is administered once on day 1 of each cycle, gemcitabine is administered once on days 1 and 8 of each cycle, albumin paclitaxel is administered once on days 1 and 8 of each cycle, and An Luoti Ni or a pharmaceutically acceptable salt thereof is administered once per day on days 1-14 of each cycle.
In some embodiments, the above uses or methods of treatment are one treatment cycle every 21 days, about 600-2400mg, 1200-1800mg, or 1800-2400mg of the anti-PD-L1 antibody-TGF-beta RII fusion protein is administered on day 1 of each cycle, 500-1000mg/m 2, or 500mg/m 2、750mg/m 2 or 1000mg/m 2 of gemcitabine is administered daily on day 1 and 8 of each cycle, 75-125mg/m 2 is administered daily on day 1 and 8 of each cycle, or 75mg/m 2、100mg/m 2 or 125mg/m 2 of albumin paclitaxel. In some embodiments, the above uses or methods of treatment are one treatment cycle every 21 days, with about 600mg, about 700mg, about 800mg, about 900mg, about 1000mg, about 1100mg, about 1200mg, about 1300mg, about 1400mg, about 1500mg, about 1600mg, about 1700mg, about 1800mg, about 1900mg, about 2000mg, about 2100mg, about 2200mg, about 2300mg, or about 2400mg of an anti-PD-L1 antibody-TGF-beta RII fusion protein administered on day 1 of each cycle, gemcitabine at 500mg/m 2、750mg/m 2 or 1000mg/m 2 is administered daily on days 1 and 8 of each cycle, and albumin paclitaxel at 75mg/m 2、100mg/m 2 or 125mg/m 2 is administered daily on days 1 and 8 of each cycle. In some embodiments, the above use or method of treatment is one treatment cycle every 21 days, about 600mg, about 1200mg, about 1800mg or about 2400mg of the anti-PD-L1 antibody-tgfbetarii fusion protein is administered on day 1 of each cycle, 500mg/m 2、750mg/m 2 or 1000mg/m 2 of gemcitabine is administered daily on days 1 and 8 of each cycle, and 75mg/m 2、100mg/m 2 or 125mg/m 2 of albumin paclitaxel is administered daily on days 1 and 8 of each cycle. In some embodiments, the above uses or methods of treatment are one treatment cycle every 21 days, about 1200mg of the anti-PD-L1 antibody-TGF-beta RII fusion protein is administered on day 1 of each cycle, 500mg/m 2、750mg/m 2 or 1000mg/m 2 of gemcitabine is administered daily on days 1 and 8 of each cycle, and 75mg/m 2、100mg/m 2 or 125mg/m 2 of albumin paclitaxel is administered daily on days 1 and 8 of each cycle. In some embodiments, the above use or method of treatment is one treatment cycle every 21 days, about 1800mg of the anti-PD-L1 antibody-TGF-beta RII fusion protein is administered on day 1 of each cycle, 500mg/m 2、750mg/m 2 or 1000mg/m 2 of gemcitabine is administered daily on days 1 and 8 of each cycle, and 75mg/m 2、100mg/m 2 or 125mg/m 2 of albumin paclitaxel is administered daily on days 1 and 8 of each cycle. In some embodiments, the above use or method of treatment is one treatment cycle every 21 days, about 1200mg of the anti-PD-L1 antibody-tgfbetarii fusion protein is administered on day 1 of each cycle, 1000mg/m 2 of gemcitabine is administered daily on days 1 and 8 of each cycle, and 125mg/m 2 of albumin paclitaxel is administered daily on days 1 and 8 of each cycle. In some embodiments, the above use or method of treatment is one treatment cycle every 21 days, about 1800mg of the anti-PD-L1 antibody-tgfbetarii fusion protein is administered on day 1 of each cycle, 1000mg/m 2 of gemcitabine is administered daily on days 1 and 8 of each cycle, and 125mg/m 2 of albumin paclitaxel is administered daily on days 1 and 8 of each cycle.
In some embodiments, the above uses or methods of treatment are one treatment cycle every 21 days, about 600-2400mg, 1200-1800mg, or 1800-2400mg of the anti-PD-L1 antibody-TGF-beta RII fusion protein is administered on day 1 of each cycle, 500-1000mg/m 2, or 500mg/m 2、750mg/m 2 or 1000mg/m 2 of gemcitabine is administered daily on day 1 and 8 of each cycle, 75-125mg/m 2 is administered daily on day 1 and 8 of each cycle, or 75mg/m 2、100mg/m 2 or 125mg/m 2 of albumin paclitaxel, 6mg, 8mg, 10mg and/or 12mg of An Luoti Ni or a pharmaceutically acceptable salt thereof, are administered daily on days 1-14 of each cycle. In some embodiments, the above uses or methods of treatment are one treatment cycle every 21 days, with about 600mg, about 700mg, about 800mg, about 900mg, about 1000mg, about 1100mg, about 1200mg, about 1300mg, about 1400mg, about 1500mg, about 1600mg, about 1700mg, about 1800mg, about 1900mg, about 2000mg, about 2100mg, about 2200mg, about 2300mg, or about 2400mg of an anti-PD-L1 antibody-TGF-beta RII fusion protein administered on day 1 of each cycle, gemcitabine at 500mg/m 2、750mg/m 2 or 1000mg/m 2 is administered daily on days 1 and 8 of each cycle, paclitaxel at 75mg/m 2、100mg/m 2 or 125mg/m 2 is administered daily on days 1 and 8 of each cycle, and paclitaxel at An Luoti, or a pharmaceutically acceptable salt thereof at 6, 8, 10, and/or 12mg daily on days 1-14 of each cycle. In some embodiments, the above uses or methods of treatment are one treatment cycle every 21 days, with about 600mg, about 1200mg, about 1800mg, or about 2400mg of the anti-PD-L1 antibody-TGF-beta RII fusion protein administered on day 1 of each cycle, 500mg/m 2、750mg/m 2 or 1000mg/m 2 of gemcitabine administered daily on days 1 and 8 of each cycle, 75mg/m 2、100mg/m 2 or 125mg/m 2 of albumin paclitaxel administered daily on days 1 and 8 of each cycle, an Luoti Ni or a pharmaceutically acceptable salt thereof is administered at 6mg, 8mg, 10mg and/or 12mg daily on days 1-14 of each cycle. In some embodiments, the above uses or methods of treatment are one treatment cycle every 21 days, about 1200mg of the anti-PD-L1 antibody-TGF-beta RII fusion protein is administered on day 1 of each cycle, 500mg/m 2、750mg/m 2 or 1000mg/m 2 of gemcitabine is administered daily on days 1 and 8 of each cycle, 75mg/m 2、100mg/m 2 or 125mg/m 2 of albumin paclitaxel is administered daily on days 1 and 8 of each cycle, 6 mg/m, An Luoti mg, 10mg and/or 12mg of An Luoti mg or a pharmaceutically acceptable salt thereof. In some embodiments, the above uses or methods of treatment are one treatment cycle every 21 days, about 1800mg of the anti-PD-L1 antibody-TGF-beta RII fusion protein is administered on day 1 of each cycle, 500mg/m 2、750mg/m 2 or 1000mg/m 2 of gemcitabine is administered daily on days 1 and 8 of each cycle, 75mg/m 2、100mg/m 2 or 125mg/m 2 of albumin paclitaxel is administered daily on days 1 and 8 of each cycle, 6 mg/m, An Luoti mg, 10mg and/or 12mg of An Luoti mg or a pharmaceutically acceptable salt thereof. In some embodiments, the above use or method of treatment is one treatment cycle every 21 days, about 1200mg of the anti-PD-L1 antibody-tgfbetarii fusion protein is administered on day 1 of each cycle, 1000mg/m 2 of gemcitabine is administered daily on days 1 and 8 of each cycle, 125mg/m 2 of albumin paclitaxel is administered daily on days 1 and 8 of each cycle, and 8mg of An Luoti of paclitaxel or a pharmaceutically acceptable salt thereof is administered daily on days 1-14 of each cycle. In some embodiments, the above use or method of treatment is one treatment cycle every 21 days, about 1800mg of the anti-PD-L1 antibody-tgfbetarii fusion protein is administered on day 1 of each cycle, 1000mg/m 2 of gemcitabine is administered daily on days 1 and 8 of each cycle, 125mg/m 2 of albumin paclitaxel is administered daily on days 1 and 8 of each cycle, and 8mg of An Luoti ni or a pharmaceutically acceptable salt thereof is administered daily on days 1-14 of each cycle.
In some embodiments, the anti-PD-L1 antibody-TGF-beta RII fusion protein, gemcitabine, and albumin paclitaxel are administered to the subject at a mass ratio of (0.1-10): 1, (0.125-2): 1, (0.125-1.5): 1 or (0.25-1.5): 1 to the anti-PD-L1 antibody-TGF-beta RII fusion protein and gemcitabine, and (0.1-30): 1, (1-15): 1, (2-15): 1 or (2-10): 1 to the anti-PD-L1 antibody-TGF-beta RII fusion protein and albumin paclitaxel. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, or albumin paclitaxel is administered in multiple doses or in a single dose. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel are administered in multiple doses.
In some embodiments, the anti-PD-L1 antibody-TGF beta RII fusion protein and gemcitabine mass ratio of (0.1-10): 1, (0.125-2): 1, (0.125-1.5): 1 or (0.25-1.5): 1, (0.1-30): 1, (1-15): 1, (2-15): 1 or (2-10): 1 to albumin paclitaxel mass ratio, and (3.5-29.0): 1, (7.1-21.5): 1, (7.1-14.5): 1, (10.5-21.5): 1, 50:7 or 75:7 anti-PD-L1 antibody-TGF beta RII fusion protein and An Luoti or pharmaceutically acceptable salt thereof are administered to the subject. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, or erlotinib, or a pharmaceutically acceptable salt thereof, is administered in multiple doses or in a single dose. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel are administered in multiple doses and An Luoti ni, or a pharmaceutically acceptable salt thereof, is administered in a single dose. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel are administered in multiple doses and An Luoti n or a pharmaceutically acceptable salt thereof is administered in a single dose at each administration.
In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein may be administered at a dose selected from the group consisting of 0.01 to 50mg/kg, 0.1 to 40mg/kg, 0.1 to 35mg/kg, 0.1 to 30mg/kg, 0.1 to 25mg/kg, 0.1 to 20mg/kg, 0.1 to 15mg/kg, 0.1 to 10mg/kg, 1 to 40mg/kg, 1 to 35mg/kg, 1 to 30mg/kg, 1 to 25mg/kg, 1 to 20mg/kg, 1 to 15mg/kg, 1 to 10mg/kg, 1 to 3mg/kg, 3 to 40mg/kg, 3 to 35mg/kg, 3 to 30mg/kg, 3 to 25mg/kg, 3 to 20mg/kg, 3 to 10mg/kg, 10 to 40mg/kg, 20 to 30mg/kg, 25 to 35mg/kg, or 30mg/kg to a subject; or a uniform dose of 60mg to 2400mg, 90mg to 2400mg, 120mg to 2400mg, 180mg to 2400mg, 300mg to 2400mg, 600mg to 2400mg, 900mg to 2400mg, 1200mg to 2400mg, 1500mg to 2400mg, 1800mg to 2400mg, 300mg to 2000mg, 600mg to 2000mg, 900mg to 2000mg, 1200mg to 2000mg, 1500mg to 2000mg, 300mg to 1800mg, 600mg to 1800mg, 900mg to 1800mg, 1200mg to 1600mg, 1400mg to 1800mg, 1500mg to 1800mg, or 1600mg to 1800 mg.
In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, calcium folinate, fluorouracil, irinotecan, and oxaliplatin are each in the form of a pharmaceutical composition for simultaneous, sequential, and/or alternative administration. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, calcium folinate, fluorouracil, irinotecan, oxaliplatin, and An Luoti ni, or a pharmaceutically acceptable salt thereof, are each in the form of a pharmaceutical composition, for simultaneous, sequential and/or alternative administration. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, calcium folinate, fluorouracil, irinotecan, and oxaliplatin are each in the form of a pharmaceutical composition and are each administered in a divided administration. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, calcium folinate, fluorouracil, irinotecan, oxaliplatin, and An Luoti ni, or a pharmaceutically acceptable salt thereof, are each in the form of a pharmaceutical composition and are each administered in a separate administration. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, calcium folinate, fluorouracil, irinotecan, and oxaliplatin are administered separately in the same or different dosing regimen. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein, calcium folinate, fluorouracil, irinotecan, oxaliplatin, and An Luoti ni, or a pharmaceutically acceptable salt thereof, are administered separately in the same or different dosing regimens.
In some embodiments, the above use or method of treatment, the calcium folinate, fluorouracil, irinotecan, and oxaliplatin are administered once every two weeks. In some embodiments, the above-described use or method of treatment, the anti-PD-L1 antibody-tgfbetarii fusion protein is administered once every three weeks, and each of calcium folinate, fluorouracil, irinotecan, and oxaliplatin is administered once every two weeks. In some embodiments, the above use or method of treatment is administered about 600mg, about 700mg, about 800mg, about 900mg, about 1000mg, about 1100mg, about 1200mg, about 1300mg, about 1400mg, about 1500mg, about 1600mg, about 1700mg, about 1800mg, about 1900mg, about 2000mg, about 2100mg, about 2200mg, about 2300mg, or about 2400mg of the anti-PD-L1 antibody-tgfbetarii fusion protein once every three weeks of 1 day, 400mg/m 2 of calcium folinate once every two weeks of 1 day, 2800mg/m 2 of fluorouracil every two weeks of 1 day, 180mg/m 2 of irinotecan administered every two weeks of 1 day, and 85mg/m 2 of oxaliplatin every two weeks of 1 day. In the above embodiments, the tumor is pancreatic cancer.
In some embodiments, the pancreatic cancer is a pancreatic endocrine tumor. In some embodiments, the pancreatic cancer is a pancreatic neuroendocrine tumor. In some embodiments, the pancreatic cancer is a pancreatic exocrine tumor. In some embodiments, the pancreatic cancer is ductal adenocarcinoma. In some embodiments, the pancreatic cancer is acinar cell cancer. In some embodiments, the pancreatic cancer is squamous carcinoma and/or adenosquamous carcinoma. In some embodiments, the pancreatic cancer is a glioblastoma (also known as mucinous non-cystic carcinoma). In some embodiments, the pancreatic cancer is a liver-like adenocarcinoma. In some embodiments, the pancreatic cancer is a medullary cancer. In some embodiments, the pancreatic cancer is invasive micro-papillary carcinoma. In some embodiments, the pancreatic cancer is a ring cell cancer. In some embodiments, the pancreatic cancer is an undifferentiated carcinoma. In some embodiments, the pancreatic cancer is pancreatic blast cancer. In some embodiments, the pancreatic cancer is a solid-pseudopapillary tumor.
In some embodiments, the pancreatic cancer is refractory, unresectable, recurrent advanced and/or metastatic pancreatic cancer. In some embodiments, the pancreatic cancer is metastatic pancreatic cancer. In some embodiments, the pancreatic cancer is advanced pancreatic cancer. In some embodiments, the pancreatic cancer is locally advanced pancreatic cancer. In some embodiments, the pancreatic cancer is advanced metastatic pancreatic cancer.
In some embodiments, the subject of pancreatic cancer has not previously been treated for pancreatic cancer (e.g., metastatic pancreatic cancer).
In some embodiments, the subject of pancreatic cancer has not previously received chemotherapy to treat pancreatic cancer (e.g., has not previously received chemotherapy in a metastatic environment).
In some embodiments, the subject of pancreatic cancer has not previously received first-line systemic chemotherapy to treat pancreatic cancer (e.g., has not previously received first-line systemic chemotherapy in a metastatic environment).
In some embodiments, the subject of pancreatic cancer has not previously received surgery, radiation therapy, and/or immunotherapy to treat pancreatic cancer (e.g., has not previously received surgery, radiation therapy, and/or immunotherapy in a metastatic environment).
In some embodiments, the subject of pancreatic cancer has not previously received adjuvant therapy to treat pancreatic cancer (e.g., has not previously received adjuvant therapy in a metastatic environment).
In some embodiments, the subject of pancreatic cancer has previously been treated with one or more different anti-tumor therapies.
In some embodiments, the subject of pancreatic cancer has previously been treated for pancreatic cancer (e.g., failed or inapplicable) with one or more of surgery, radiation therapy, chemotherapy, and immunotherapy.
In some embodiments, the subject of pancreatic cancer has been treated with chemotherapy for pancreatic cancer (e.g., failed treatment or is unsuitable for chemotherapy).
In some embodiments, the subject of pancreatic cancer has been treated with a first-line systemic chemotherapy regimen (e.g., failed treatment or inapplicable to systemic chemotherapy). In some embodiments, the subject of pancreatic cancer develops disease progression during the first-line treatment or progresses after the treatment is completed.
In some embodiments, the subject of pancreatic cancer has been treated with FOLFIRINOX regimen (combination chemotherapy of calcium folinate, fluorouracil, irinotecan, and oxaliplatin) with pancreatic cancer (e.g., treatment failure or inapplicability to systemic chemotherapy).
In some embodiments, the subject of pancreatic cancer has been treated with a FOLFIRINOX regimen in combination with a breast cancer susceptible protein (BRCA) mutation targeted treatment regimen (e.g., failed or inapplicable). In some embodiments, the BRCA mutation targeted therapy regimen includes, but is not limited to, PARP inhibitors, such as olapari.
In some embodiments, the subject of pancreatic cancer has been treated with a PD-1/PD-L1 inhibitor therapy for pancreatic cancer. In some embodiments, the subject of pancreatic cancer is an insufficient responder to a PD-1/PD-L1 inhibitor. In some embodiments, the subject of pancreatic cancer is refractory to treatment with a PD-1/PD-L1 inhibitor, e.g., after at least 2 doses.
In some embodiments, the subject of pancreatic cancer has been treated (e.g., failed or inapplicable) with a FOLFIRINOX regimen in combination with a PD-1/PD-L1 inhibitor treatment regimen.
In some embodiments, the PD-1/PD-L1 inhibitor therapy is an anti-PD-1 antibody, such as nal Wu Liyou mab (Nivolumab), pamil mab (Pembrolizumab), terlipressin Li Shan mab (JS-001), singal Li Shan mab (IBI 308), karellizumab (Camrelizumab), tirelimumab (BGB-a 317), batelimumab (Balstilimab), AK105, jernomumab (GB 226), LZM009, HLX10, AK103 (HX 008), CS1003, SCT-I10A, F520, SG001, or sirolimumab (GLS-010).
In some embodiments, the PD-1/PD-L1 inhibitor therapy is an anti-PD-L1 antibody, such as, for example, atilizumab (Atezolizumab), dulcis You Shan anti (Durvalumab), alikumab (Avelumab), en Wo Lishan anti (KN 035), shu Geli mab (CS 1001), TQB2450, SHR-1316, socazolimab (ZKAB 001), HS636, LP002, JS003, MSB2311, KL-a167, or STI-a1014.
In some embodiments, the subject of pancreatic cancer has been treated with a treatment regimen comprising tegafur (e.g., failed or inapplicable to treatment).
In some embodiments, the subject of pancreatic cancer has been treated (e.g., failed or inapplicable) with a treatment regimen comprising a platinum group (e.g., oxaliplatin and/or cisplatin).
In some embodiments, the subject of pancreatic cancer has been treated with neoadjuvant chemotherapy or adjuvant chemotherapy regimen (e.g., failed or inapplicable).
In some embodiments, the subject of pancreatic cancer has been treated with neoadjuvant chemotherapy or a adjuvant chemotherapy regimen, and disease progression or recurrence occurs during neoadjuvant chemotherapy or adjuvant therapy or within 6 months after the end of therapy.
In some embodiments, the subject of pancreatic cancer has been treated for pancreatic cancer with localized radiation therapy (e.g., failed or inapplicable).
In some embodiments, the subject of pancreatic cancer has been treated with localized radiation therapy, and localized radiation therapy has ended for more than 4 weeks (brain radiation therapy for more than 2 weeks), and the target lesion of the current study is not within the radiation therapy region, or the target lesion is within the radiation therapy region, but progression has been confirmed.
Anti-PD-L1 antibody-TGF-beta RII fusion protein
The anti-PD-L1 antibody-TGF-beta RII fusion protein comprises:
(a) An anti-PD-L1 antibody or antigen-binding fragment thereof; and
(B) Tgfβ binding domains.
In some embodiments, the TGF-beta binding domain is a human TGF-beta RII or TGF-beta binding fragment thereof, e.g., a polypeptide or peptide fragment having an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence set forth in SEQ ID NO. 28, or a fragment of any of the text.
In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof comprises: heavy chain CDR (HCDR) 1 shown in SEQ ID NO. 1 or SEQ ID NO. 12, HCDR2 shown in SEQ ID NO. 2 or SEQ ID NO. 13, HCDR3 shown in SEQ ID NO. 3 or SEQ ID NO. 14, light chain CDR (LCDR) 1 shown in SEQ ID NO. 4 or SEQ ID NO. 15, LCDR2 shown in SEQ ID NO. 5 or SEQ ID NO. 16, and LCDR3 shown in SEQ ID NO. 6 or SEQ ID NO. 17.
In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof comprises: HCDR1 shown in SEQ ID No.1, HCDR2 shown in SEQ ID No. 2, HCDR3 shown in SEQ ID No. 3, LCDR1 shown in SEQ ID No. 4, LCDR2 shown in SEQ ID No. 5, and LCDR3 shown in SEQ ID No. 6; or HCDR1 shown in SEQ ID NO. 12, HCDR2 shown in SEQ ID NO. 13, HCDR3 shown in SEQ ID NO. 14, LCDR1 shown in SEQ ID NO. 15, LCDR2 shown in SEQ ID NO.16, and LCDR3 shown in SEQ ID NO. 17. The CDR sequences described above are provided in table 1 below.
TABLE 1 CDR sequences
In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof comprises a heavy chain variable domain having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO. 7 or SEQ ID NO. 18, and a light chain variable domain having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO. 8 or SEQ ID NO. 19. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof comprises a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO. 7 or SEQ ID NO. 18 and a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO. 8 or SEQ ID NO. 19. In some specific embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof comprises a heavy chain variable domain of the amino acid sequence set forth in SEQ ID NO. 7 and a light chain variable domain of the amino acid sequence set forth in SEQ ID NO. 8. In other specific embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof comprises a heavy chain variable domain of the amino acid sequence set forth in SEQ ID NO. 18 and a light chain variable domain of the amino acid sequence set forth in SEQ ID NO. 19.
In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof may further comprise a constant region of an immunoglobulin, or a fragment, analog, variant, or derivative of the constant region. In some embodiments, the constant region is from a human immunoglobulin heavy chain, such as the heavy chain of IgG1, igG2, igG3, and IgG4 or other classes of immunoglobulins, preferably the heavy chain of IgG 1. In some embodiments, the constant region may comprise any of the modifications described herein, such as amino acid insertions, deletions, substitutions, or chemical modifications. In some embodiments, the constant region comprises a mutation that alters effector function, e.g., mutates a lysine residue at the C-terminal end of the antibody constant region to a hydrophobic amino acid, such as alanine or leucine, reducing hydrolytic cleavage by proteases, increasing serum half-life. In some embodiments, any amino acid residue of the constant region may be substituted with an amino acid residue of any allotype (allotype), preferably with an amino acid residue of G1m (3) and/or nG1m (1).
In some embodiments, the anti-PD-L1 antibody comprises a heavy chain having an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO 9, SEQ ID NO 20, SEQ ID NO 23, or SEQ ID NO 25, and a light chain having an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO 10 or SEQ ID NO 21. In some embodiments, the anti-PD-L1 antibody comprises a heavy chain having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO. 9 or SEQ ID NO. 23, and a light chain having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO. 10. In other embodiments, the anti-PD-L1 antibody comprises a heavy chain having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO. 20 or SEQ ID NO. 25, and a light chain having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO. 21.
In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein further comprises a linking peptide that links the C-terminus of the anti-PD-L1 antibody or antigen binding fragment thereof to the N-terminus of the tgfbeta binding domain; alternatively, the tgfβ binding domain is human tgfβrii or a tgfβ binding fragment thereof. The connecting peptide can adopt flexible connecting peptide or rigid connecting peptide; alternatively, the linker peptide is formed by combining glycine and serine, for example, (G 4S) x G wherein x is optionally an integer from 3 to 6, preferably 4 or 5, most preferably 4 (i.e., the amino acid sequence shown in SEQ ID NO: 29)) a linker peptide-free linker may be used.
In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein comprises an anti-PD-L1 antibody, or antigen-binding fragment thereof, and a tgfbeta binding domain; the antibody or antigen binding fragment thereof may optionally comprise an unmodified or modified constant region, e.g., the C-terminal K of the constant region is mutated to a, or an allotype amino acid substitution; the TGF-beta binding domain comprises a human TGF-beta RII or a fragment or variant thereof capable of binding TGF-beta, such as an extracellular domain of human TGF-beta RII. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein comprises: (a) The amino acid sequence has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence shown in SEQ ID NO. 7 and the heavy chain variable domain and amino acid sequence has at least 80%, 81%, 82% identity to the amino acid sequence shown in SEQ ID NO. 8, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical light chain variable domain, or a heavy chain variable domain and amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence shown in SEQ ID NO:18 has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical light chain variable domain; and (b) a TGF-beta binding domain. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein comprises: (a) A heavy chain variable domain shown in SEQ ID NO. 7 and a light chain variable domain shown in SEQ ID NO. 8, or a heavy chain variable domain shown in SEQ ID NO. 18 and a light chain variable domain shown in SEQ ID NO. 19; and (b) a TGF-beta binding domain. In some embodiments, the TGF-beta binding domain is human TGF-beta RII or a TGF-beta binding fragment or variant thereof, e.g., a polypeptide or peptide fragment having an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence set forth in SEQ ID NO. 28.
In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein comprises: (a) The heavy chain and amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity of the amino acid sequence with the amino acid sequence shown in SEQ ID NO. 9 has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical light chain or heavy chain and amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence shown in SEQ ID NO. 20 has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical light chain; and (b) a TGF-beta binding domain. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein comprises: (a) The heavy chain and amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity of the amino acid sequence with the amino acid sequence shown in SEQ ID NO. 23 has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical light chain, or heavy chain and amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence shown in SEQ ID NO. 25 has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical light chain; and (b) a TGF-beta binding domain. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein comprises: (a) A heavy chain shown in SEQ ID NO. 9 and a light chain shown in SEQ ID NO. 10, or a heavy chain shown in SEQ ID NO. 20 and a light chain shown in SEQ ID NO. 21; and (b) a TGF-beta binding domain. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein comprises: (a) A heavy chain shown in SEQ ID NO. 23 and a light chain shown in SEQ ID NO. 10, or a heavy chain shown in SEQ ID NO. 25 and a light chain shown in SEQ ID NO. 21; and (b) a TGF-beta binding domain. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein comprises: (a) A heavy chain shown in SEQ ID NO. 25 and a light chain shown in SEQ ID NO. 21; and (b) a TGF-beta binding domain. In some embodiments, the TGF-beta binding domain is human TGF-beta RII or a TGF-beta binding fragment or variant thereof, e.g., a polypeptide or peptide fragment having an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence set forth in SEQ ID NO. 28.
In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein comprises: (a) A first polypeptide having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO. 11, SEQ ID NO. 22, SEQ ID NO. 24 or SEQ ID NO. 26, and (b) a second polypeptide having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO. 10 or SEQ ID NO. 21. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein comprises: (a) A first polypeptide having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO. 11 or SEQ ID NO. 24, and (b) a second polypeptide having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO. 10. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein comprises: (a) A first polypeptide having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO. 22 or SEQ ID NO. 26, and (b) a second polypeptide having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO. 21.
In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein comprises: (a) A first polypeptide having an amino acid sequence as shown in SEQ ID NO. 11 or SEQ ID NO. 24, and (b) a second polypeptide having an amino acid sequence as shown in SEQ ID NO. 10. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein comprises: (a) A first polypeptide having an amino acid sequence as set forth in SEQ ID NO. 22 or SEQ ID NO. 26, and (b) a second polypeptide having an amino acid sequence as set forth in SEQ ID NO. 21.
In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein comprises: (a) A first polypeptide having an amino acid sequence as set forth in SEQ ID NO. 26, and (b) a second polypeptide having an amino acid sequence as set forth in SEQ ID NO. 21.
In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein consists of two identical first polypeptides and two identical second polypeptides, wherein: (a) The amino acid sequence of the first polypeptide has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence shown in SEQ ID NO. 11, SEQ ID NO. 22, SEQ ID NO. 24 or SEQ ID NO. 26; and (b) the amino acid sequence of the second polypeptide has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence shown in SEQ ID NO. 10 or SEQ ID NO. 21. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein consists of two identical first polypeptides and two identical second polypeptides, wherein: (a) The amino acid sequence of the first polypeptide is shown as SEQ ID NO. 11 or SEQ ID NO. 24; and the amino acid sequence of the second polypeptide is shown as SEQ ID NO. 10. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein consists of two identical first polypeptides and two identical second polypeptides, wherein: (a) The amino acid sequence of the first polypeptide is shown as SEQ ID NO. 22 or SEQ ID NO. 26; and the amino acid sequence of the second polypeptide is shown as SEQ ID NO. 21. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein consists of two identical first polypeptides and two identical second polypeptides, wherein: (a) The amino acid sequence of the first polypeptide is shown as SEQ ID NO. 26; and the amino acid sequence of the second polypeptide is shown as SEQ ID NO. 21. Wherein the amino acid sequence of the first polypeptide is as follows from the N-terminal to the C-terminal: the sequence of an antibody heavy chain variable domain, an antibody heavy chain constant region, a linker peptide, a tgfβ binding fragment of human tgfβrii that recognizes a PD-L1 epitope or antigen.
In other embodiments, the anti-PD-L1 antibody-TGF-beta RII fusion protein is an anti-PD-L1 antibody-TGF-beta receptor II fusion protein in CN 106103488.
In other embodiments, the anti-PD-L1 antibody-TGF-beta RII fusion protein is a PD-L1/TGF-beta trap fusion protein in CN 110050000.
In other embodiments, the anti-PD-L1 antibody-TGF-beta RII fusion protein is a Bi-PLB-1 fusion protein of WO 2020006509.
Pharmaceutical composition containing anti-PD-L1 antibody-TGF beta RII fusion protein
In some embodiments, the unit dose of the pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein is 200-1200mg or other amount of an anti-PD-L1 antibody-tgfbetarii fusion protein, e.g., 200mg, 250mg, 300mg, 350mg, 400mg, 450mg, 500mg, 550mg, 600mg, 700mg, 800mg, 900mg, 1000mg, 1100mg, 1200mg or other amount of an anti-PD-L1 antibody-tgfbetarii fusion protein.
In some embodiments, the concentration of the anti-PD-L1 antibody-tgfbetarii fusion protein in the pharmaceutical composition comprising the anti-PD-L1 antibody-tgfbetarii fusion protein is 1mg/mL to 200mg/mL, 2mg/mL to 150mg/mL, 5mg/mL to 100mg/mL, 10mg/mL to 80mg/mL, 10mg/mL to 60mg/mL, or 10mg/mL to 50mg/mL. In some specific embodiments, the concentration of the anti-PD-L1 antibody-TGF-beta RII fusion protein is about 10mg/mL, about 15mg/mL, about 20mg/mL, about 25mg/mL, about 30mg/mL, about 35mg/mL, about 40mg/mL, about 45mg/mL, about 50mg/mL, about 55mg/mL, about 60mg/mL, about 80mg/mL, or about 100mg/mL. In some embodiments, the concentration of the anti-PD-L1 antibody-TGF-beta RII fusion protein is about 20mg/mL. In some embodiments, the concentration of the anti-PD-L1 antibody-TGF-beta RII fusion protein is about 25mg/mL. In some embodiments, the concentration of the anti-PD-L1 antibody-TGF-beta RII fusion protein is about 40mg/mL. In other embodiments, the concentration of the anti-PD-L1 antibody-TGF-beta RII fusion protein is about 50mg/mL.
In some embodiments, the pharmaceutical composition comprising the anti-PD-L1 antibody-TGF-beta RII fusion protein may further comprise one or more physiologically acceptable excipients or carriers to form a suitable formulation. Suitable formulations for use in the present disclosure can be found in Lemmington pharmaceutical sciences, 17 th edition, mark publishing company (Mack PublishingCompany), iston, pa., 1985. In some embodiments, the pharmaceutical composition comprising the anti-PD-L1 antibody-tgfbetarii fusion protein further comprises one or more of a buffer, an isotonicity modifier, a stabilizer, and a surfactant. In some embodiments, the anti-PD-L1 antibody-tgfbetarii fusion protein-containing pharmaceutical composition further comprises a buffer, a stabilizer, and a surfactant.
In a specific embodiment, the pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein is a water-soluble injection, including, but not limited to, a water-soluble formulation that has not been lyophilized or a water-soluble formulation that has been reconstituted from a lyophilized powder. In other embodiments, the pharmaceutical composition comprising an anti-PD-L1 antibody-tgfbetarii fusion protein is a lyophilized formulation. The lyophilized preparation refers to a preparation prepared by subjecting an aqueous solution to a lyophilization process in which a substance is first frozen, then the amount of solvent is reduced by sublimation (primary drying process) and then the amount of solvent is reduced by desorption (secondary drying process) until the amount of solvent is a value that no longer supports biological activity or chemical reaction. The lyophilized formulations of the present disclosure may also be dried by other methods known in the art, such as spray drying and bubble drying (bubble drying).
Gemcitabine
As used in the present disclosure, the gemcitabine has the chemical name 2' -deoxy-2 ',2' -difluorocytidine (β -isomer) having the structural formula (I):
As used in the present disclosure, the gemcitabine includes both its free base form and a pharmaceutically acceptable salt, and such non-salt forms or salts are within the scope of the present disclosure. Gemcitabine may be administered in the form of its free base or in the form of its pharmaceutically acceptable salt. Pharmaceutically acceptable salts of e.g. gemcitabine are within the scope of the present disclosure, which salts may be produced according to methods well known in the art from different organic and inorganic acids, e.g. the inorganic acid may be selected from hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid or phosphoric acid, the organic acid may be selected from succinic acid, maleic acid, acetic acid, fumaric acid, citric acid, tartaric acid, benzoic acid, p-toluenesulfonic acid or methanesulfonic acid. In some embodiments, the pharmaceutically acceptable salt of gemcitabine may be the hydrochloride salt of gemcitabine.
In some embodiments of the present disclosure, gemcitabine is administered in the form of its hydrochloride salt. In some embodiments, the gemcitabine is administered in the form of its monohydrochloride.
The doses of gemcitabine referred to in this disclosure are based on the molecular weight of the compound of formula (I) unless otherwise indicated.
Gemcitabine-containing pharmaceutical composition
In some embodiments of the present disclosure, the unit dose of the gemcitabine-containing pharmaceutical composition is 0.2g or 1.0g of gemcitabine.
In some embodiments, the gemcitabine-containing pharmaceutical composition is a formulation including, but not limited to, a formulation suitable for intravenous, oral, parenteral, topical administration. In some embodiments, the gemcitabine-comprising pharmaceutical composition is a formulation suitable for injection. In some embodiments, the gemcitabine-comprising pharmaceutical composition is a liquid formulation. In some embodiments, the gemcitabine-comprising pharmaceutical composition is a liquid formulation suitable for injection. In some embodiments, the gemcitabine-comprising pharmaceutical composition is a liquid formulation suitable for intravenous injection. In some embodiments, the gemcitabine-comprising pharmaceutical composition is a lyophilized formulation. In some embodiments, the gemcitabine-comprising pharmaceutical composition is a lyophilized formulation suitable for injection. In some embodiments, the gemcitabine-comprising pharmaceutical composition is a lyophilized formulation suitable for intravenous injection.
The lyophilized formulation suitable for injection may be prepared by conventional methods using pharmaceutically acceptable carriers well known in the art. Pharmaceutically acceptable carriers include fillers, absorbents, wetting agents, binders, disintegrants, lubricants, and the like. In a particular embodiment, the pharmaceutically acceptable carrier of the lyophilized formulation suitable for injection comprises mannitol, sodium acetate, hydrochloric acid, sodium hydroxide.
Albumin taxol
As used in the present disclosure, the albumin paclitaxel is albumin-bound paclitaxel; the chemical name of the taxol is 5 beta, 20-epoxy-1, 2 alpha, 4,7 beta, 10 beta, 13 alpha-hexahydroxytaxane-11-alkene-9-ketone-4, 10-diacetate-2-benzoate-13- (2R, 3S) -N-benzoyl-3-phenylisoserine ester, which has the structural formula (II):
the doses of albumin paclitaxel referred to in the present disclosure are based on the molecular weight of the compound of formula (II), unless otherwise indicated.
Pharmaceutical composition containing albumin paclitaxel
In some embodiments of the present disclosure, the unit dose of the albumin-containing pharmaceutical composition is 100mg of albumin paclitaxel comprising 100mg of paclitaxel and about 900mg of human serum albumin.
In some embodiments, the pharmaceutical composition comprising albumin paclitaxel is a formulation including, but not limited to, a formulation suitable for intravenous, oral, parenteral, topical administration. In some embodiments, the pharmaceutical composition comprising albumin paclitaxel is a formulation suitable for injection. In some embodiments, the gemcitabine-comprising pharmaceutical composition is a liquid formulation. In some embodiments, the pharmaceutical composition comprising albumin paclitaxel is a liquid formulation suitable for injection. In some embodiments, the pharmaceutical composition comprising albumin paclitaxel is a liquid formulation suitable for intravenous injection. In some embodiments, the pharmaceutical composition comprising albumin paclitaxel is a lyophilized formulation. In some embodiments, the pharmaceutical composition comprising albumin paclitaxel is a lyophilized formulation suitable for injection. In some embodiments, the pharmaceutical composition comprising albumin paclitaxel is a lyophilized formulation suitable for intravenous injection.
In addition, paclitaxel prepared in other formulations is also contemplated within the scope of the present disclosure, such as paclitaxel injection, paclitaxel oral liquid, paclitaxel liposome, and the like.
An Luoti Ni or a pharmaceutically acceptable salt thereof
As used in the present disclosure, the An Luoti ni has the chemical name 1- [ [ [4- (4-fluoro-2-methyl-1H-indol-5-yl) oxy-6-methoxyquinolin-7-yl ] oxy ] methyl ] cyclopropylamine having the structural formula (III):
As used in the present disclosure, erlotinib may be administered in its free base form or in the form of a pharmaceutically acceptable salt thereof. Pharmaceutically acceptable salts of An Luoti, for example, are within the scope of this disclosure, which salts may be produced according to methods well known in the art from different organic and inorganic acids, for example, the inorganic acid may be selected from hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid, and the organic acid may be selected from succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic or methanesulfonic acid. In some embodiments, the pharmaceutically acceptable salt of An Luoti n may be the hydrochloride salt of An Luoti n (e.g., the dihydrochloride salt of An Luoti n).
In some embodiments of the present disclosure, an Luoti n is administered in the form of its hydrochloride salt. In some embodiments, the administration is in the form of An Luoti nim-hydrochloride. In some embodiments of the present disclosure, the administration is in the form of An Luoti nim dihydrochloride. In some embodiments, the administration is in the crystalline form of An Luoti% of the hydrochloride salt. In a particular embodiment, the pharmaceutical composition is administered in the form of a crystalline form of An Luoti nim dihydrochloride.
Dosages of An Luoti Ni or a pharmaceutically acceptable salt thereof referred to in this disclosure are based on the molecular weight of the compound of formula (III), unless otherwise indicated.
Pharmaceutical composition containing An Luoti Ni or pharmaceutically acceptable salt thereof
In some embodiments of the present disclosure, the unit dose of the pharmaceutical composition comprising An Luoti ni or a pharmaceutically acceptable salt thereof is 6mg, 8mg, 10mg, or 12mg An Luoti ni.
An Luoti Ni or a pharmaceutically acceptable salt thereof is preferably suitable for oral formulations including tablets, capsules, powders, granules, dripping pills, pastes, powders and the like, preferably tablets and capsules. Wherein the tablet can be common tablet, dispersible tablet, effervescent tablet, sustained release tablet, controlled release tablet or enteric-coated tablet, and the capsule can be common capsule, sustained release capsule, controlled release capsule or enteric-coated capsule. The oral formulations may be prepared by conventional methods using pharmaceutically acceptable carriers well known in the art. Pharmaceutically acceptable carriers include fillers, absorbents, wetting agents, binders, disintegrants, lubricants, and the like.
In one embodiment, the pharmaceutical composition comprising An Luoti n or a pharmaceutically acceptable salt thereof is a solid formulation suitable for oral administration. In one embodiment, the pharmaceutical composition comprising An Luoti% or a pharmaceutically acceptable salt thereof may be in the form of a tablet or capsule. In a particular embodiment, the pharmaceutical composition comprising An Luoti% or a pharmaceutically acceptable salt thereof is in the form of a capsule. In a particular embodiment, the pharmaceutically acceptable carrier of the oral solid formulation of An Luoti ni or a pharmaceutically acceptable salt thereof comprises mannitol, microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate.
Mode of administration
The following is not intended to limit the manner of administration of the pharmaceutical combinations of the present disclosure.
The components of the pharmaceutical combinations of the present disclosure may each be administered independently, or some or all of them together, in a suitable variety of routes, including, but not limited to, oral or parenteral (via intravenous, intramuscular, topical or subcutaneous routes). In some embodiments, the components of the pharmaceutical combinations of the present disclosure may each be administered orally or by injection, e.g., intravenous, subcutaneous, or intraperitoneal, independently, or some or all of them together.
The components of the pharmaceutical combinations of the present disclosure may each independently, or some or all of them together, be in a suitable dosage form, including, but not limited to, tablets, troches, pills, capsules (e.g., hard, soft, enteric, microcapsules), elixirs, granules, syrups, injections (intramuscular, intravenous, intraperitoneal, subcutaneous), granules, emulsions, suspensions, solutions, dispersions, and dosage forms of sustained release formulations for oral or non-oral administration.
The components of the pharmaceutical combinations of the present disclosure may each independently, or some or all of them together contain a pharmaceutically acceptable carrier and/or excipient.
The pharmaceutical combinations of the present disclosure may also comprise additional therapeutic agents. In one embodiment, the additional therapeutic agent may be a cancer therapeutic agent known in the art.
Technical effects
Generally, the use of the pharmaceutical combinations of the present disclosure described above will help:
(1) Producing a better therapeutic effect in reducing the growth of or even eliminating the tumor than either drug administered alone in the combination;
(2) Providing a smaller amount of administration compared to either drug administered alone in the combination;
(3) Providing a treatment with good tolerance in the patient with fewer adverse reactions and/or complications than either drug administered alone;
(4) Providing better disease control rate among treated patients;
(5) Providing a longer survival (e.g., median survival, progression free survival, or total survival) in the treated patient;
(6) Providing a longer survival (e.g., median survival, progression free survival, or total survival) for the treated patient compared to standard chemotherapy;
(7) Provide longer duration of disease remission (DOR); and/or
(8) Compared with any one of the medicines singly administered in the combination, the composition has good activity of treating pancreatic cancer and shows more excellent anti-tumor synergistic effect.
Definition and description
The following terms used in this disclosure have the following meanings, unless otherwise indicated. A particular term, unless otherwise defined, shall not be construed as being ambiguous or otherwise unclear, but shall be construed in accordance with the ordinary meaning in the art. When trade names are presented in this disclosure, it is intended to refer to their corresponding commercial products or active ingredients thereof.
As used herein, the term "pharmaceutical combination" refers to a combination of two or more active ingredients administered simultaneously or sequentially (either as the respective active ingredients themselves or as derivatives, prodrugs or compositions of their respective pharmaceutically acceptable salts or esters). The active ingredients may each be administered to the subject simultaneously as a single formulation, or sequentially in any order, each as a single formulation.
The term "fixed combination" refers to the simultaneous administration of the active ingredients in a fixed total dose or dose ratio, or in the form of a single entity, pharmaceutical composition or formulation, to a subject.
The term "non-fixed combination" refers to the simultaneous, concurrent or sequential administration of two or more active ingredients as separate entities (e.g., pharmaceutical compositions, formulations) to a subject, wherein the administration of the active ingredients to the subject achieves a therapeutically effective amount level. An example of a non-fixed combination is a cocktail therapy, e.g., administration of 3 or more active ingredients. In a non-fixed combination, the individual active ingredients may be packaged, marketed or administered as a fully independent pharmaceutical composition. The term "non-immobilized combination" also includes the use of "immobilized combinations" between, or in combination with, separate entities of any one or more of the active ingredients.
"TGF-beta RII" or "TGF-beta receptor II" refers to a polypeptide or protein having a wild-type human TGF-beta receptor 2 isoform B sequence, such as the polypeptide shown in SEQ ID NO. 27, or a polypeptide having a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%,86%,87%,88%,89%,90%,91%,92%,93%,94%,95%,96%,97%,98%,99% or 100% identical to the amino acid sequence shown in SEQ ID NO. 27.
"Fragment of TGF-beta binding-fragment" or "TGF-beta binding-fragment" of TGF-beta RII refers to a fragment of TGF-beta RII that has TGF-beta binding activity that is about at least 0.1%, 0.5%, 1%, 5%, 10%, 25%, 35%, 50%, 75%, 90%, 95%, 99% or 100% of the TGF-beta RII sequence. Such fragments are typically soluble fragments, such as the extracellular domain of human TGF-beta RII or variants thereof, non-limiting examples of which include the polypeptides shown in SEQ ID NO. 28.
As used herein, the term "antibody" refers to a binding protein having at least one antigen binding domain. The antibodies and antigen binding fragments thereof of the present disclosure may be whole antibodies or any fragment of an antibody. Thus, antibodies and antigen binding fragments thereof of the present disclosure include monoclonal antibodies or fragments thereof and antibody variants or fragments thereof, as well as immunoconjugates. Examples of antibody fragments include Fab fragments, fab ' fragments, F (ab) '2 fragments, fv fragments, fd ' fragments, isolated CDR regions, single chain Fv molecules (scFv) and other antibody fragments known in the art, as well as antibodies that have been subjected to any modification known in the art (e.g., glycosylation modification, chemical modification, etc.). Antibodies and antigen binding fragments thereof may also include recombinant polypeptides, fusion proteins, and bispecific antibodies. The anti-PD-L1 antibodies and antigen-binding fragments thereof disclosed herein may be of the IgG1, igG2, igG3 or IgG4 isotype. The term "isotype" refers to the type of antibody encoded by the heavy chain constant region gene. The antibodies and antigen binding fragments thereof may be chimeric, humanized or fully human antibodies.
"Chimeric antibody" is the following antibody: the antibodies have at least a portion of a heavy chain variable domain and at least a portion of a light chain variable domain derived from a species; and at least a portion of a constant region derived from another species. For example, in one embodiment, a chimeric antibody may comprise a murine variable domain and a human constant region.
"Humanized antibodies" are the following antibodies: the antibodies contain Complementarity Determining Regions (CDRs) derived from a non-human antibody; and framework and constant regions derived from human antibodies. For example, an anti-PD-L1 antibody may comprise CDRs derived from one or more murine antibodies as well as human framework and constant regions. Exemplary humanized antibodies are provided herein. Additional anti-PD-L1 antibodies or variants thereof comprising HCDR and LCDR provided herein can be generated using any human framework sequences and are also included in the disclosure. In one embodiment, framework sequences suitable for use in the present disclosure include those framework sequences that are similar in structure to the framework sequences provided herein. Additional modifications may be made in the framework regions to improve the properties of the antibodies provided herein. Such additional framework modifications may include chemical modifications; point mutations to reduce immunogenicity or to remove T cell epitopes; or reverting the mutation to a residue in the original germline sequence. In some embodiments, such modifications include those corresponding to the mutations exemplified herein, including back mutations to germline sequences. For example, in one embodiment, one or more amino acids in the human framework regions of VH and/or VL of a humanized antibody provided herein are back mutated to corresponding amino acids in a parent murine antibody.
"Antigen binding fragment" refers to a fragment that retains the antigen binding function of a full length antibody, including Fab, fab ', F (ab ') 2, scFv, fv, fd, fd ', isolated CDR regions, and single domain VHH fragments, and other antibody fragments known in the art, or any modification of the above fragments known in the art.
"Identity" refers to the similarity between two reference sequences and percent identity refers to the percentage of sequences or designated regions of sequences that are compared by sequence comparison algorithms well known to those skilled in the art.
The term "treating" refers to attempting to alter the natural course of a disease in a treated individual and may be in order to prevent, ameliorate or eliminate the disease or one or more symptoms associated with the disease, including but not limited to preventing the occurrence or recurrence of the disease, alleviating symptoms, reducing any direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, improving or alleviating the disease state, and regression or improved prognosis.
The term "effective amount" means an amount of a compound of the present disclosure that (i) treats a particular disease, condition, or disorder, (ii) alleviates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein. The amount of active agent (e.g., fusion protein or compound of the present disclosure) that comprises a "therapeutically effective amount" can vary depending on factors such as the disease state, age, sex, and weight of the individual, and the ability of the therapeutic agent or combination of therapeutic agents to elicit a desired response in the individual. An effective amount can also be routinely determined by one of ordinary skill in the art based on its own knowledge and disclosure.
The term "administering" means physically introducing a composition comprising a therapeutic agent into a subject using any of a variety of methods and delivery systems known to those of skill in the art.
Routes of administration of fusion proteins (e.g., anti-PD-L1 antibody-tgfbetarii fusion proteins) include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, such as by injection or infusion. The phrase "parenteral administration" as used herein refers to modes of administration other than enteral and topical administration, typically by injection, and includes, but is not limited to, intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion, and in vivo electroporation. Administration may also be performed, for example, one, multiple times, and/or over one or more extended periods of time.
The amount of anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, calcium folinate, fluorouracil, irinotecan, oxaliplatin, and/or An Luoti ni or a pharmaceutically acceptable salt thereof administered may be determined or adjusted depending on the severity of the disease, the response of the disease, any treatment-related toxicity, the age and health of the patient. For example, in some embodiments, a single dose of gemcitabine may be :100-3000mg/m 2、500-3000mg/m 2、600-2500mg/m 2、200-2000mg/m 2、800-2000mg/m 2、500-1500mg/m 2、500-1000mg/m 2 or 1000-1500mg/m 2. In some embodiments, the single dose of gemcitabine may be :100mg/m 2、200mg/m 2、500mg/m 2、600mg/m 2、750mg/m 2、800mg/m 2、1000mg/m 2、1500mg/m 2、2000mg/m 2、2500mg/m 2 or 3000mg/m 2. In some embodiments, a single dose of gemcitabine may be 600-4800mg. For another example, in some embodiments, a single dose of albumin paclitaxel may be :10-500mg/m 2、30-400mg/m 2、30-300mg/m 2、50-300mg/m 2、100-200mg/m 2、50-200mg/m 2、50-150mg/m 2 or 75-125mg/m 2. In some embodiments, the single dose of albumin paclitaxel may be :10mg/m 2、30mg/m 2、50mg/m 2、75mg/m 2、100mg/m 2、125mg/m 2、150mg/m 2、175mg/m 2、200mg/m 2、300mg/m 2、400mg/m 2 or 500mg/m 2. In some embodiments, a single dose of albumin paclitaxel may be 90-300mg. For another example, the daily dose of An Luoti or a pharmaceutically acceptable salt thereof may be 3-30mg, 5-20mg, or 6-12mg. In some embodiments, the daily dose of An Luoti ni, or a pharmaceutically acceptable salt thereof, administered may be 3mg, 4mg, 5mg, 6mg, 8mg, 10mg, or 12mg. Gemcitabine, albumin paclitaxel, calcium folinate, fluorouracil, irinotecan, and/or oxaliplatin may be administered once or more times per week. An Luoti Ni or a pharmaceutically acceptable salt thereof may be administered one or more times daily. In some embodiments, the gemcitabine and albumin paclitaxel are administered once a week in an injectable formulation; preferably, the administration is once a week in an intravenous formulation. In some embodiments, an Luoti ni, or a pharmaceutically acceptable salt thereof, is administered once daily in an oral solid formulation.
The dosing regimen (e.g., dosing cycle, etc.) of the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, calcium folinate, fluorouracil, irinotecan, oxaliplatin, and/or An Luoti ni or a pharmaceutically acceptable salt thereof can be determined or adjusted in combination depending on the activity, toxicity, tolerance of the patient, etc. of the drug. For example, one treatment cycle of an anti-PD-L1 antibody-tgfbetarii fusion protein may be adjusted to 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks or more. In some embodiments, the gemcitabine and albumin paclitaxel are administered once a week. In some embodiments, an Luoti ni, or a pharmaceutically acceptable salt thereof, is administered once daily. In some embodiments, each of gemcitabine and albumin paclitaxel is administered at intervals, for example, 7 weeks off for 1 week, 3 weeks off for 1 week, 2 weeks off for 2 weeks, or 2 weeks off for 1 week; the intermittent administration mode can be repeated for a plurality of times. In some embodiments, an Luoti or a pharmaceutically acceptable salt thereof is administered at intervals, for example 2 weeks off for 2 weeks, 1 week off for 2 weeks, or 2 days off for 5 days off for 2 days on a continuous basis; the intermittent administration mode can be repeated for a plurality of times. The interval administration includes administration period and withdrawal period, and can be administered once or multiple times daily during administration period. In some embodiments, gemcitabine, albumin paclitaxel, or An Luoti% of its pharmaceutically acceptable salts are administered for 2 weeks, followed by 1 week of discontinuation. In some embodiments, gemcitabine is administered intravenously at a dose of 500mg/m 2、750mg/m 2 or 1000mg/m 2 gemcitabine once a week for 2 weeks, for 1 week. In some embodiments, the albumin paclitaxel is administered intravenously at a dose of 75mg/m 2、100mg/m 2 or 125mg/m 2 albumin paclitaxel once a week for 2 weeks, for 1 week. In some embodiments, an Luoti ni, or a pharmaceutically acceptable salt thereof, is orally administered at a dose of 6mg, 8mg, 10mg, or 12mg An Luoti ni once daily for 2 weeks, for 1 week.
The use of the term "flat dose" refers to the dose administered to a patient irrespective of the weight or Body Surface Area (BSA) of the patient. The uniform dose is therefore specified as an absolute amount of agent (e.g., anti-PD-L1 antibody-tgfbetarii fusion protein) rather than as a mg/kg dose. For example, 60kg human and 100kg human will receive the same dose of antibody (e.g., 1800mg anti-PD-L1 antibody-TGF-beta RII fusion protein).
The term "pharmaceutically acceptable" is intended to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The term "pharmaceutically acceptable salts" includes salts of a base ion with a free acid or salts of a acid ion with a free base, including for example, hydrochloride, hydrobromide, nitrate, sulfate, phosphate, formate, acetate, trifluoroacetate, fumarate, oxalate, maleate, citrate, tartrate, succinate, methanesulfonate, benzoate, benzenesulfonate or p-toluenesulfonate salts, preferably hydrochloride, hydrobromide, sulfate, formate, acetate, trifluoroacetate, fumarate, maleate, methanesulfonate, p-toluenesulfonate, sodium, potassium, ammonium, amino acid salts and the like.
The terms "subject," "patient," or "subject" are used interchangeably herein. In some embodiments, the term "subject," "patient," or "subject" is a mammal. In some embodiments, the subject, patient or subject is a mouse. In some embodiments, the subject, patient or subject is a human.
As used herein, "about" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, depending in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" may mean within 1 or more than 1 standard deviation per the practice of the art. Or "about" may mean a range of up to + -5%, e.g., fluctuating within + -2%, within + -1%, or within + -0.5% of a given specific numerical range. When a particular value is given in the disclosure or claims, unless otherwise indicated, the meaning of "about" is to be considered within the acceptable error range for that particular value. In this context, unless otherwise indicated, the values of step parameters or conditions are by default modified by "about".
As used herein, "combined" or "combined" means that two or more active substances can each be administered to a subject simultaneously as a single formulation, or each as a single formulation sequentially in any order.
The term "single dose" refers to the smallest unit of packaging containing a quantity of a drug, e.g., a box of seven capsules, a capsule being a single dose; or one bottle of injection is in single dose. The term "multi-dose" consists of a plurality of single doses.
"Unit dose" refers to the dosage of the active ingredient contained in the smallest packaging unit containing a quantity of pharmaceutical product, e.g., an Luoti Ni contained in a single capsule of An Luoti Ni hydrochloride as a unit dose; or the dosage of the fusion protein contained in a bottle of fusion protein injection is unit dosage; or the dosage of paclitaxel contained in a bottle of albumin paclitaxel lyophilized powder is unit dosage.
The term "pharmaceutical composition" refers to a mixture of one or more active ingredients of the present disclosure or pharmaceutical combinations thereof and a pharmaceutically acceptable carrier. The purpose of the pharmaceutical composition is to facilitate administration of a compound of the present disclosure, or a pharmaceutical combination thereof, to a subject. The terms "pharmaceutical composition" and "formulation" have the same meaning and are used interchangeably herein.
The term "recurrent" cancer is a cancer that regenerates at an initial site or a distant site after responding to an initial treatment (e.g., surgery). A "locally recurrent" cancer is a cancer that occurs at the same location after treatment as the previously treated cancer.
The term "metastatic" cancer refers to cancer that spreads from one part of the body (e.g., the lungs) to another part of the body.
As used herein, "failure to treat" is defined as the occurrence of disease progression or recurrence during or after the last treatment.
All patents, patent applications, and other identified publications are expressly incorporated herein by reference for the purpose of description and disclosure. These publications are provided solely for their disclosure prior to the filing date of the present disclosure. All statements as to the date or representation as to the contents of these documents are based on the information available to the applicant and do not constitute any admission as to the correctness of the dates or contents of these documents. Moreover, any reference to such publications in this document does not constitute an admission that the publications are part of the common general knowledge in the art, in any country.
The present disclosure also provides some specific embodiments below, but the scope of protection of the present disclosure is not limited thereto:
Embodiment 1. A pharmaceutical combination comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel.
Embodiment 2. The pharmaceutical combination according to embodiment 1, wherein the pharmaceutical combination comprises an anti-PD-L1 antibody-TGF-beta RII fusion protein in a unit dose of 200-1200mg, gemcitabine in a unit dose of 0.2g and/or 1.0g, and albumin paclitaxel in a unit dose of 100 mg.
Embodiment 3. The pharmaceutical combination according to embodiment 1 or 2, wherein the mass ratio of the anti-PD-L1 antibody-TGF-beta RII fusion protein to gemcitabine is (0.1-10): 1 and the mass ratio of the anti-PD-L1 antibody-TGF-beta RII fusion protein to albumin paclitaxel is (0.1-30): 1.
Embodiment 4. The pharmaceutical combination according to any one of embodiments 1-3, wherein the pharmaceutical combination is suitable for administration within a single treatment cycle comprising 600-2400mg of the anti-PD-L1 antibody-tgfbetarii fusion protein, 1000-2000mg/m 2 of gemcitabine, and 150-250mg/m 2 of albumin paclitaxel.
Embodiment 5. The pharmaceutical combination according to any one of embodiments 1-4, wherein the anti-PD-L1 antibody-tgfbetarii fusion protein comprises:
(a) An anti-PD-L1 antibody or antigen-binding fragment thereof; and
(B) Human tgfβrii or a tgfβ binding fragment thereof;
Wherein the anti-PD-L1 antibody or antigen-binding fragment thereof comprises:
(a) HCDR1 of the amino acid sequence shown in SEQ ID NO. 1, HCDR2 of the amino acid sequence shown in SEQ ID NO. 2, HCDR3 of the amino acid sequence shown in SEQ ID NO. 3, LCDR1 of the amino acid sequence shown in SEQ ID NO. 4, LCDR2 of the amino acid sequence shown in SEQ ID NO. 5, and LCDR3 of the amino acid sequence shown in SEQ ID NO. 6; or (b)
(B) HCDR1 of the amino acid sequence shown in SEQ ID NO. 12, HCDR2 of the amino acid sequence shown in SEQ ID NO. 13, HCDR3 of the amino acid sequence shown in SEQ ID NO. 14, LCDR1 of the amino acid sequence shown in SEQ ID NO. 15, LCDR2 of the amino acid sequence shown in SEQ ID NO. 16, and LCDR3 of the amino acid sequence shown in SEQ ID NO. 17.
Embodiment 6. The pharmaceutical combination according to embodiment 5, wherein the anti-PD-L1 antibody or antigen-binding fragment thereof comprises:
(a) A heavy chain variable domain of the amino acid sequence shown in SEQ ID NO. 7, and a light chain variable domain of the amino acid sequence shown in SEQ ID NO. 8; or (b)
(B) A heavy chain variable domain of the amino acid sequence shown in SEQ ID NO. 18, and a light chain variable domain of the amino acid sequence shown in SEQ ID NO. 19.
Embodiment 7. The pharmaceutical combination according to embodiment 5 or 6, wherein the anti-PD-L1 antibody or antigen-binding fragment thereof comprises:
(a) A heavy chain having an amino acid sequence at least 95% identical to the amino acid sequence shown in SEQ ID NO. 9 or SEQ ID NO. 23, and a light chain having an amino acid sequence at least 95% identical to the amino acid sequence shown in SEQ ID NO. 10; or (b)
(B) A heavy chain having an amino acid sequence at least 95% identical to the amino acid sequence shown in SEQ ID NO. 20 or SEQ ID NO. 25, and a light chain having an amino acid sequence at least 95% identical to the amino acid sequence shown in SEQ ID NO. 21.
Embodiment 8. The pharmaceutical combination according to any of embodiments 5-7, wherein the human TGF-beta RII or TGF-beta binding fragment thereof comprises an amino acid sequence having at least 80% identity to the amino acid sequence set forth in SEQ ID NO. 28.
Embodiment 9. The pharmaceutical combination of any one of embodiments 5-8, wherein the anti-PD-L1 antibody-tgfbetarii fusion protein further comprises a connecting peptide that links the C-terminus of the anti-PD-L1 antibody or antigen-binding fragment thereof to the N-terminus of the human tgfbetarii or tgfbetabinding fragment thereof; preferably, the linker peptide is (G4S) x G, x is an integer from 3 to 6; preferably, the linker peptide has the amino acid sequence shown in SEQ ID NO. 29.
Embodiment 10. The pharmaceutical combination according to any one of embodiments 5-9, wherein the anti-PD-L1 antibody-tgfbetarii fusion protein comprises:
(a) A first polypeptide having an amino acid sequence at least 95% identical to the amino acid sequence shown in SEQ ID NO. 11 or SEQ ID NO. 24, and a second polypeptide having an amino acid sequence at least 95% identical to the amino acid sequence shown in SEQ ID NO. 10; or (b)
(B) A first polypeptide having an amino acid sequence at least 95% identical to the amino acid sequence shown in SEQ ID NO. 22 or SEQ ID NO. 26, and a second polypeptide having an amino acid sequence at least 95% identical to the amino acid sequence shown in SEQ ID NO. 21.
Embodiment 11. The pharmaceutical combination according to any one of embodiments 1-10, wherein the pharmaceutical combination further comprises An Luoti ni or a pharmaceutically acceptable salt thereof; optionally, the pharmaceutically acceptable salt of An Luoti is a monohydrochloride or dihydrochloride.
Embodiment 12. The pharmaceutical combination according to embodiment 11, wherein the unit dose of An Luoti n or a pharmaceutically acceptable salt thereof is 6mg, 8mg, 10mg and/or 12mg.
Embodiment 13. The pharmaceutical combination according to embodiment 11 or 12, wherein the mass ratio of the anti-PD-L1 antibody-TGF-beta RII fusion protein to An Luoti Ni or a pharmaceutically acceptable salt thereof is (3.5-29.0): 1.
Embodiment 14. The pharmaceutical combination according to any one of embodiments 11-13, wherein the pharmaceutical combination is suitable for administration within a single treatment cycle, the dose of An Luoti n or a pharmaceutically acceptable salt thereof being 84-168mg.
Embodiment 15 the pharmaceutical combination according to any one of embodiments 1-14, wherein the pharmaceutical combination is for use in the treatment of pancreatic cancer.
Embodiment 16. Use of the pharmaceutical combination of any of embodiments 1-15 in the manufacture of a medicament for the treatment of pancreatic cancer.
Embodiment 17. The use according to embodiment 16, wherein the pancreatic cancer is refractory, unresectable, recurrent, advanced and/or metastatic pancreatic cancer; preferably, the pancreatic cancer is metastatic pancreatic cancer.
Embodiment 18. The use according to embodiment 16 or 17, wherein the pancreatic cancer is a pancreatic endocrine tumor and/or a pancreatic exocrine tumor.
Embodiment 19 the use of any one of embodiments 16-18, wherein the subject of pancreatic cancer has not previously been treated for pancreatic cancer.
Embodiment 20. The use according to any of embodiments 16-18, wherein the subject of pancreatic cancer has previously been treated with one or more different anti-tumor treatment methods.
Embodiment 21 the use according to any one of embodiments 16-20, wherein the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine and albumin paclitaxel are each in the form of a pharmaceutical composition, which may be administered simultaneously, sequentially and/or alternately.
Embodiment 22. The use of any of embodiments 16-20, wherein the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, albumin paclitaxel, and An Luoti ni, or a pharmaceutically acceptable salt thereof, are each in the form of a pharmaceutical composition, which may be administered simultaneously, sequentially, and/or alternately.
Embodiment 23 the use of any one of embodiments 16-22, wherein the anti-PD-L1 antibody-tgfbetarii fusion protein is administered once every 1 week, every 2 weeks, every 3 weeks, or every 4 weeks, each at a dose of 600-2400mg of the anti-PD-L1 antibody-tgfbetarii fusion protein.
Embodiment 24 the use of any one of embodiments 16-23, wherein the gemcitabine is administered in a dosage of 500-1000mg/m 2、500mg/m 2、750mg/m 2 or 1000mg/m 2 gemcitabine once a week, on a 2 week, off 1 week regimen.
Embodiment 25 the use according to any one of embodiments 16-24, wherein the albumin paclitaxel is administered in a dose of 75-125mg/m 2、75mg/m 2、100mg/m 2 or 125mg/m 2 albumin paclitaxel once a week, on a 2 week, off 1 week regimen.
Embodiment 26. The use according to any of embodiments 16-20, 22-25, wherein said An Luoti ni or pharmaceutically acceptable salt thereof is administered in a dose of 6-12mg, 6mg, 8mg, 10mg or 12mg An Luoti ni once daily, on a2 week, off 1 week regimen.
Embodiment 27 a kit for treating pancreatic cancer comprising the pharmaceutical combination of any one of embodiments 1-15.
For clarity, the disclosure is further illustrated with examples, but the examples do not limit the scope of the disclosure. All reagents used in the present disclosure are commercially available and can be used without further purification.
Methods for preparing and purifying anti-PD-L1 antibody-TGF-beta RII fusion proteins of the present disclosure are described in WO2021037184, the entire contents of which WO2021037184 is incorporated into the present disclosure. The anti-PD-L1 antibody-TGF-beta RII fusion protein hu5G11-hIgG 1-TGF-beta RII in the examples is hu5G11-hIgG 1-TGF-beta RII in WO2021037184, said hu5G11-hIgG 1-TGF-beta RII consisting of two identical first polypeptides and two identical second polypeptides, wherein: (1) The amino acid sequence of the first polypeptide is shown as SEQ ID NO. 26, the first polypeptide is a fusion protein which consists of a heavy chain of an anti-human PD-L1 antibody (SEQ ID NO. 25), an extracellular domain amino acid sequence of human TGF-beta RII (SEQ ID NO. 28) and a G 4S) 4 G connecting peptide (SEQ ID NO. 29) connecting the heavy chain and the extracellular domain amino acid sequence of human TGF-beta RII (SEQ ID NO. 21), and the amino acid sequence of the second polypeptide is shown as SEQ ID NO. 21.
The amino acid sequence of the hu5G11-hIgG 1-TGF-beta RII first polypeptide (SEQ ID NO: 26):
The amino acid sequence of the hu5G11-hIgG 1-TGF-beta RII second polypeptide (SEQ ID NO: 21):
Example 1: clinical trial of advanced metastatic pancreatic cancer
1. Criteria for inclusion
(1) Subjects voluntarily joined the study and signed informed consent;
(2) Age 18-75 years (time to sign informed consent);
(3) Stage 1, requiring the inclusion of patients who failed prior to at least one line of systemic chemotherapy or who the researcher deems unsuitable for receiving systemic chemotherapy;
stage 2, cohort 1 and cohort 2, require inclusion of primary histologically or cytologically confirmed metastatic pancreatic cancer patients;
cohort 3, stage 2, requires inclusion of metastatic pancreatic cancer patients following first line FOLFIRINOX or folfirinox+brca mutation targeted therapy or failure of PD-1/PD-L1 therapy;
Note that: definition of first line treatment failure: a. disease progression occurs during the course of first-line therapy or after the end of therapy; b. disease progression was within 6 months after neoadjuvant or adjuvant therapy.
(4) Stage 1 requires that there be at least one evaluable lesion as evidenced by RECIST 1.1 criteria; stage 2 requires that there be at least one measurable lesion as demonstrated according to RECIST 1.1 criteria;
(5) ECOG scores 0-1 score, expected lifetime greater than 3 months;
(6) The main organ functions well, meeting the following criteria:
1) Blood routine examination criteria (no blood transfusion, no correction with hematopoietic stimulatory factor type drug within 7 days prior to examination):
a) Hemoglobin (HGB) is more than or equal to 90g/L;
b) The absolute value (NEUT) of the neutrophil is more than or equal to 1.5X10 9/L;
c) Platelet count (PLT) was ≡100× 9/L.
2) The biochemical examination needs to meet the following criteria:
a) Total Bilirubin (TBIL) is less than or equal to 1.5 times the upper limit of normal value (ULN) (biliary tract scaffolds are allowed);
b) Alanine Aminotransferase (ALT) and aspartic acid Aminotransferase (AST) are less than or equal to 2.5 XULN. If liver metastasis is accompanied, ALT and AST are less than or equal to 5 XULN;
c) Serum Creatinine (CR) is less than or equal to 1.5 XULN or Creatinine Clearance (CCR) is less than or equal to 60mL/min.
3) The coagulation function is required to meet the following criteria:
International Normalized Ratio (INR) is less than or equal to 1.5 x ULN (anticoagulation treatment not received);
4) Thyroid function examination should meet the following criteria:
Thyroid Stimulating Hormone (TSH) is less than or equal to ULN; if the abnormality should examine the levels of triiodothyronine (T3) and thyroxine (T4), T3 and T4 levels are normal, then inclusion may be made.
5) Heart color Doppler ultrasound evaluation: left Ventricular Ejection Fraction (LVEF) is greater than or equal to 50%.
(7) Patients must take reliable contraceptive measures during the study period and within 6 months after the end of the study period; serum pregnancy/urinary pregnancy tests were negative within 7 days prior to study entry and had to be non-lactating subjects; male subjects should agree that contraceptive measures must be taken during the study period and within 6 months after the end of the study period;
2. Test drug
Hu5G11-hIgG1-TGFβRII injection: specifications were 200mg (4 mL)/bottle and 600mg (12 mL)/bottle;
gemcitabine: specifications of 0.2 g/bottle and 1.0 g/bottle;
albumin paclitaxel: the specification is 100 mg/bottle;
an Luoti Ni capsule of hydrochloric acid: specifications were 6 mg/pellet, 8 mg/pellet, 10 mg/pellet and 12 mg/pellet.
3. Dosing regimen
3.1 Stage 1:
hu5G11-hIgG1-TGFβRII injection: 600mg, 1200mg, 1800mg or 2400mg, is administered by intravenous drip once every 3 weeks for 1 treatment cycle every 3 weeks.
3.2 Phase 2:
queue 1: hu5G11-hIgG 1-tgfbetarii injection + gemcitabine + albumin paclitaxel first line treatment:
hu5G11-hIgG1-TGFβRII injection: 600mg, 1200mg, 1800mg or 2400mg, for intravenous drip, once every 21 days;
Gemcitabine: 1000mg/m 2, intravenous drip, once every 7 days, for 2 weeks and 1 week stop;
Albumin paclitaxel: 125mg/m 2, intravenous drip, once every 7 days, for 2 weeks and 1 week stop;
order of administration: the hu5G11-hIgG1-TGF beta RII injection, the albumin paclitaxel and the gemcitabine were infused first.
Queue 2: hu5G11-hIgG1-TGFβRII injection+ An Luoti Nib hydrochloride capsule+gemcitabine+albumin paclitaxel first line treatment:
hu5G11-hIgG1-TGFβRII injection: 600mg, 1200mg, 1800mg or 2400mg, for intravenous drip, once every 21 days;
an Luoti Ni capsule of hydrochloric acid: 8mg, orally taken, 1 time daily, for 2 weeks and 1 week stop;
Gemcitabine: 1000mg/m 2, intravenous drip, once every 7 days, for 2 weeks and 1 week stop;
Albumin paclitaxel: 125mg/m 2, intravenous drip, once every 7 days, for 2 weeks and 1 week stop;
Order of administration: oral administration of An Luoti Ni hydrochloride capsule, infusion of hu5G11-hIgG1-TGF beta RII injection, albumin taxol, and finally gemcitabine.
Queue 3: hu5G11-hIgG 1-tgfbetarii injection + gemcitabine + albumin paclitaxel two-line treatment:
hu5G11-hIgG1-TGFβRII injection: 600mg, 1200mg, 1800mg or 2400mg, for intravenous drip, once every 21 days;
Gemcitabine: 1000mg/m 2, intravenous drip, once every 7 days, for 2 weeks and 1 week stop;
Albumin paclitaxel: 125mg/m 2, intravenous infusion, once every 7 days, for 2 weeks and 1 week stop.
Order of administration: the hu5G11-hIgG1-TGF beta RII injection, the albumin paclitaxel and the gemcitabine were infused first.
Drug delay or dose down-regulation is allowed during the study depending on the subject's situation, but not cross-dose down-regulation: for example, the dose of albumin paclitaxel is adjusted from 125mg/m 2 to 100mg/m 2, or from 100mg/m 2 to 75mg/m 2; the dose of gemcitabine is adjusted from 1000mg/m 2 to 750mg/m 2, or from 750mg/m 2 to 500mg/m 2.
4. Evaluation criteria
The disease state is judged by adopting RECIST 1.1 standard as a main rule, and the curative effect is confirmed and supplemented by iRECIST standard.
5. Endpoint index
Objective Remission Rate (ORR) = (complete remission (CR) +partial remission (PR));
disease control rate (dcr=cr+pr+disease Stabilization (SD)), duration of remission (DOR), progression Free Survival (PFS), total survival (OS);
incidence and severity of Adverse Events (AEs);
Immunogenicity, such as the incidence of anti-drug antibodies (ADA) and their titers in a subject, the incidence of neutralizing antibodies (Nab).
And evaluating the relationship between the therapeutic related biomarkers, such as PD-L1 in tumor tissue and the anti-tumor effect of TGF-beta and hu5G11-hIgG1-TGFβRII injection in blood sample.
6. Therapeutic effects
After the subjects with metastatic pancreatic cancer are subjected to first-line treatment by hu5G11-hIgG1-TGF beta RII injection (1200 mg) +gemcitabine+albumin paclitaxel, the clinical curative effect and survival benefit can be remarkably improved, and in 8 subjects diagnosed with metastatic pancreatic cancer, 2 subjects (patient A and patient B) achieve partial remission PR (25%), and tumors of a plurality of subjects in subjects with Stable Disease (SD) are reduced by more than 20%; specific exemplary results are described below.
The subjects with metastatic pancreatic cancer can significantly improve clinical efficacy and survival benefit after first-line treatment by hu5G11-hIgG1-TGF beta RII injection (600 mg-1800 mg) + An Luoti Nicapsule hydrochloride+gemcitabine+albumin paclitaxel, and among 4 subjects diagnosed with metastatic pancreatic cancer (patient C, patient D, patient E and patient F), all subjects achieve Partial Remission (PR); specific exemplary results are described below.
Preliminary results show that hu5G11-hIgG1-TGF beta RII, gemcitabine and albumin paclitaxel are used in combination, and hu5G11-hIgG1-TGF beta RII, gemcitabine, albumin paclitaxel and An Luoti Ni hydrochloride capsules are used in combination, so that metastatic pancreatic cancer can be safely and effectively treated, and the potential advantages of prolonging the progression-free survival FPS and the total survival OS of metastatic pancreatic cancer subjects are achieved.
6.1 Pre-treatment diagnostic results
Patient a:
Metastatic pancreatic cancer: hepatobiliary pancreatic tumors and vascular CTA show that pancreatic cancer at the tail of the pancreas involves splenomegaly with local infarction of the spleen, multiple metastasis of the liver, multiple implantation and metastasis of the peritoneum omentum system membrane, and splenomegaly. Patients were subjected to needle biopsies and pathology revealed that (liver puncture specimens) poorly differentiated cancers metastasized or infiltrated.
Patient B:
Metastatic pancreatic cancer: hepatobiliary pancreatic tumors and vascular CTA (hepatobiliary pancreatic spleen) show that the pancreatic duct expands; expansion of intrahepatic bile duct; retroperitoneal multiple slightly larger lymph nodes; liver S4 takes place, considering metastasis; multiple cysts of liver; the hepatic left artery and the gastric left artery are co-dried; multiple cysts of both kidneys. Performing a needle biopsy on the liver of a patient; immunohistochemistry showed that pancreas (S4 segment of liver puncture specimen) infiltrated or metastasized, suggesting the pancreatic bile duct phenotype.
Patients C-F:
metastatic pancreatic cancer.
6.2 Treatment Effect and evaluation
Patient a:
screening period: target lesions: 81.61mm;
After period 2 dosing: target lesions: 65.16mm;
after period 4 dosing: target lesions: 47.7mm;
according to the efficacy evaluation criteria, the optimal therapeutic effect is PR.
Patient B:
screening period: target lesions: 33.10mm;
after period 2 dosing: target lesions: 17.7mm;
according to the efficacy evaluation criteria, the optimal therapeutic effect is PR.
Patient C:
Screening period: target lesions: 90.9mm;
after period 2 dosing: target lesions: 63.1mm;
according to the efficacy evaluation criteria, the optimal therapeutic effect is PR.
Patient D:
screening period: target lesions: 66.79mm;
After period 2 dosing: target lesions: 46.2mm;
after period 4 dosing: target lesions: 37.9mm;
according to the efficacy evaluation criteria, the optimal therapeutic effect is PR.
Patient E:
Screening period: target lesions: 79.19mm;
After period 2 dosing: target lesions: 39.3mm;
according to the efficacy evaluation criteria, the optimal therapeutic effect is PR.
Patient F:
Screening period: target lesions: 53.06mm;
After period 2 dosing: target lesions: 47.9mm;
After period 4 dosing: target lesions: 35.3mm;
according to the efficacy evaluation criteria, the optimal therapeutic effect is PR.
Claims (15)
- A pharmaceutical combination comprising an anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel; wherein the anti-PD-L1 antibody-tgfbetarii fusion protein comprises:(a) An anti-PD-L1 antibody or antigen-binding fragment thereof; and(B) Human tgfβrii or a tgfβ binding fragment thereof;Wherein the anti-PD-L1 antibody or antigen-binding fragment thereof comprises:(a) HCDR1 of the amino acid sequence shown in SEQ ID NO. 12, HCDR2 of the amino acid sequence shown in SEQ ID NO. 13, HCDR3 of the amino acid sequence shown in SEQ ID NO. 14, LCDR1 of the amino acid sequence shown in SEQ ID NO. 15, LCDR2 of the amino acid sequence shown in SEQ ID NO. 16, and LCDR3 of the amino acid sequence shown in SEQ ID NO. 17;(b) HCDR1 of the amino acid sequence shown in SEQ ID NO. 1, HCDR2 of the amino acid sequence shown in SEQ ID NO. 2, HCDR3 of the amino acid sequence shown in SEQ ID NO. 3, LCDR1 of the amino acid sequence shown in SEQ ID NO. 4, LCDR2 of the amino acid sequence shown in SEQ ID NO. 5, and LCDR3 of the amino acid sequence shown in SEQ ID NO. 6;(c) A heavy chain variable domain of the amino acid sequence shown in SEQ ID NO. 18, and a light chain variable domain of the amino acid sequence shown in SEQ ID NO. 19;(d) A heavy chain variable domain of the amino acid sequence shown in SEQ ID NO. 7, and a light chain variable domain of the amino acid sequence shown in SEQ ID NO. 8;(e) A heavy chain having at least 95% identity in amino acid sequence to the amino acid sequence shown in SEQ ID NO. 20 or SEQ ID NO. 25, and a light chain having at least 95% identity in amino acid sequence to the amino acid sequence shown in SEQ ID NO. 21; or (b)(F) A heavy chain having an amino acid sequence at least 95% identical to the amino acid sequence shown in SEQ ID NO. 9 or SEQ ID NO. 23, and a light chain having an amino acid sequence at least 95% identical to the amino acid sequence shown in SEQ ID NO. 10.
- A pharmaceutical combination according to claim 1, wherein the human tgfβrii or tgfβ binding fragment thereof comprises an amino acid sequence having at least 80% identity to the amino acid sequence set forth in SEQ ID No. 28.
- The pharmaceutical combination of claim 1 or 2, wherein the anti-PD-L1 antibody-tgfbetarii fusion protein further comprises a linking peptide that links the C-terminus of the anti-PD-L1 antibody or antigen-binding fragment thereof to the N-terminus of the human tgfbetarii or tgfbeta binding fragment thereof; preferably, the linker peptide is (G4S) x G, x is an integer from 3 to 6; preferably, the linker peptide has the amino acid sequence shown in SEQ ID NO. 29.
- A pharmaceutical combination according to any one of claims 1-3, wherein the anti-PD-L1 antibody-tgfbetarii fusion protein comprises:(a) A first polypeptide having an amino acid sequence at least 95% identical to the amino acid sequence shown in SEQ ID NO. 22 or SEQ ID NO. 26, and a second polypeptide having an amino acid sequence at least 95% identical to the amino acid sequence shown in SEQ ID NO. 21; or (b)(B) A first polypeptide having an amino acid sequence at least 95% identical to the amino acid sequence shown in SEQ ID NO. 11 or SEQ ID NO. 24, and a second polypeptide having an amino acid sequence at least 95% identical to the amino acid sequence shown in SEQ ID NO. 10.
- A pharmaceutical combination according to any one of claims 1-4, wherein the pharmaceutical combination comprises an anti-PD-L1 antibody-tgfbetarii fusion protein in a unit dose of 200-1200mg, gemcitabine in a unit dose of 0.2g and/or 1.0g, and albumin paclitaxel in a unit dose of 100 mg.
- The pharmaceutical combination according to any one of claims 1-5, wherein the mass ratio of the anti-PD-L1 antibody-tgfbetarii fusion protein to gemcitabine is (0.1-10): 1 and the mass ratio of the anti-PD-L1 antibody-tgfbetarii fusion protein to albumin paclitaxel is (0.1-30): 1.
- A pharmaceutical combination according to any one of claims 1-6, wherein the pharmaceutical combination is suitable for administration within a single treatment cycle comprising 600-2400mg of an anti-PD-L1 antibody-tgfbetarii fusion protein, 1000-2000mg/m 2 of gemcitabine, and 150-250mg/m 2 of albumin paclitaxel.
- The pharmaceutical combination of any one of claims 1-7, wherein the pharmaceutical combination further comprises An Luoti ni or a pharmaceutically acceptable salt thereof; optionally, the pharmaceutically acceptable salt of An Luoti is a monohydrochloride or dihydrochloride.
- The pharmaceutical combination according to claim 8, wherein the pharmaceutical combination comprises An Luoti ni or a pharmaceutically acceptable salt thereof in unit dose of 6mg, 8mg, 10mg and/or 12 mg; alternatively, the anti-PD-L1 antibody-TGF-beta RII fusion protein and An Luoti Ni or a pharmaceutically acceptable salt thereof are present in a mass ratio of (3.5-29.0) to 1; optionally, the pharmaceutical combination is suitable for administration within a single treatment cycle, the pharmaceutical combination further comprising 84-168mg An Luoti ni or a pharmaceutically acceptable salt thereof.
- Use of a pharmaceutical combination according to any one of claims 1-9 for the manufacture of a medicament for the treatment of pancreatic cancer; preferably, the pancreatic cancer is refractory, unresectable, recurrent, advanced and/or metastatic pancreatic cancer; more preferably, the pancreatic cancer is metastatic pancreatic cancer.
- The use of claim 10, wherein the pancreatic cancer is a pancreatic endocrine tumor and/or a pancreatic exocrine tumor.
- The use of claim 10 or 11, wherein the subject of pancreatic cancer has not previously been treated for pancreatic cancer; or (b)The subject of pancreatic cancer has previously been treated with one or more different anti-tumor therapies.
- The use of any one of claims 10-12, wherein the anti-PD-L1 antibody-tgfbetarii fusion protein, gemcitabine, and albumin paclitaxel are each in the form of a pharmaceutical composition for simultaneous, sequential, and/or alternate administration; or (b)The anti-PD-L1 antibody-TGF-beta RII fusion protein, gemcitabine, albumin paclitaxel, and An Luoti n or a pharmaceutically acceptable salt thereof are each in the form of a pharmaceutical composition that may be administered simultaneously, sequentially, and/or alternately.
- The use of any one of claims 10-13, wherein the anti-PD-L1 antibody-tgfbetarii fusion protein is administered once every 1 week, every 2 weeks, every 3 weeks, or every 4 weeks, each at a dose of 600-2400mg of anti-PD-L1 antibody-tgfbetarii fusion protein;Optionally, the gemcitabine is administered in a dosage of 500-1000mg/m 2、500mg/m 2、750mg/m 2 or 1000mg/m 2 gemcitabine once a week, on a 2 week, 1 week stop regimen;Optionally, the albumin paclitaxel is administered in a dose of 75-125mg/m 2、75mg/m 2、100mg/m 2 or 125mg/m 2 albumin paclitaxel once a week, on a 2 week, 1 week stop regimen;optionally, the An Luoti-or pharmaceutically acceptable salt thereof is administered in a dose of 6-12mg, 6mg, 8mg, 10mg, or 12mg An Luoti-of-one-day, on a continuous 2-week, 1-week-stop dosing regimen.
- A kit for treating pancreatic cancer comprising the pharmaceutical combination of any one of claims 1-9.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111247635 | 2021-10-26 | ||
CN2021112476358 | 2021-10-26 | ||
PCT/CN2022/127280 WO2023072043A1 (en) | 2021-10-26 | 2022-10-25 | Combined drug for treating tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118176017A true CN118176017A (en) | 2024-06-11 |
Family
ID=86160385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280066732.3A Pending CN118176017A (en) | 2021-10-26 | 2022-10-25 | Combined medicine for treating tumor |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN118176017A (en) |
WO (1) | WO2023072043A1 (en) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2018128464A (en) * | 2016-02-25 | 2020-03-25 | Селл Медика Свитзерленд Аг | BINDING ELEMENTS AGAINST PD-L1 |
CA3118415A1 (en) * | 2018-11-09 | 2020-05-14 | Jiangsu Hengrui Medicine Co., Ltd. | Tgf-.beta. receptor fusion protein pharmaceutical composition and use thereof |
WO2020181214A1 (en) * | 2019-03-07 | 2020-09-10 | Advenchen Pharmaceuticals, LLC | Using catequentinib (anlotinib) combining with standard chemotherapy or immunotherapy in sequential order for the cancer treatment |
US20220289825A1 (en) * | 2019-08-30 | 2022-09-15 | Nanjing Shunxin Pharmaceuticals Co., Ltd., Of Chiatai Tianqing Pharmaceutical Group | FUSION PROTEIN TARGETING PD-L1 AND TGF-ß AND USE THEREOF |
JP2023507620A (en) * | 2019-12-20 | 2023-02-24 | アレス トレーディング ソシエテ アノニム | IgG:TGFβRII fusion protein compositions |
CN115135675A (en) * | 2020-02-18 | 2022-09-30 | 南京金斯瑞生物科技有限公司 | Fusion proteins and uses thereof |
CN113318226A (en) * | 2020-02-28 | 2021-08-31 | 正大天晴药业集团股份有限公司 | Method for treating lung cancer by anti-PD-L1 antibody and radioactive rays |
CN114984204A (en) * | 2021-03-02 | 2022-09-02 | 正大天晴药业集团股份有限公司 | Combined medicine for treating tumor |
CN112940134B (en) * | 2021-05-11 | 2021-09-03 | 正大天晴药业集团南京顺欣制药有限公司 | Bifunctional proteins against PD-1 and TGF-beta |
-
2022
- 2022-10-25 CN CN202280066732.3A patent/CN118176017A/en active Pending
- 2022-10-25 WO PCT/CN2022/127280 patent/WO2023072043A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2023072043A8 (en) | 2024-02-15 |
WO2023072043A1 (en) | 2023-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113347996B (en) | Combined pharmaceutical composition for treating tumors | |
EP3347054B1 (en) | Dosing regimens for anti-tf-antibody drug-conjugates | |
TW201922793A (en) | Uses of PD-1 antibody combined with VEGFR inhibitor for treating small cell lung cancer | |
WO2020187152A1 (en) | Combined pharmaceutical composition for treating small cell lung cancer | |
AU2015225646A1 (en) | Anti-MET in combination with anti-VEGFR2 antibodies therapy for cancer | |
CN113939315B (en) | Combined pharmaceutical composition for treating melanoma | |
WO2020249018A1 (en) | Combined pharmaceutical composition for treating driver-gene-positive lung cancer | |
CN113018429A (en) | Pharmaceutical composition for treating ovarian cancer | |
JP2023502585A (en) | Combined inhibition of PD-1, TGFβ, and TIGIT for the treatment of cancer | |
CN114340679A (en) | Methods and medicaments for treating cancers that are non-responsive to inhibitors of PD-1/PD-L1 signaling | |
WO2021244551A1 (en) | Combined pharmaceutical composition of c-met kinase inhibitor and anti-pd-l1 antibody | |
WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor | |
CN118176017A (en) | Combined medicine for treating tumor | |
CN113117072A (en) | Pharmaceutical composition of quinoline derivative and PD-1 monoclonal antibody | |
KR20200105825A (en) | Use of the combination therapy of PD-1 antibody and Afatinib for the treatment of triple negative breast cancer | |
WO2023174408A1 (en) | Pharmaceutical combination of anti-tim-3 antibody and anti-pd-l1 antibody | |
CN117224689B (en) | Use of a combination of an anti-HER 2 antibody and a chemotherapeutic agent for the treatment of gastric cancer | |
WO2023174278A1 (en) | Pharmaceutical composition of anti-tim-3 antibody and hypomethylating agent | |
WO2022270523A1 (en) | Medicament for treatment and/or prevention of cancer | |
CN118526572A (en) | Pharmaceutical combination of c-Met kinase inhibitor and anti-PD-1 antibody-TGF-beta RII fusion protein | |
CN117085124A (en) | Pharmaceutical composition comprising anti-PD-L1 antibody and c-Met kinase inhibitor | |
CN117085123A (en) | Pharmaceutical combination of an anti-PD-L1 antibody and a c-Met kinase inhibitor | |
KR20240046526A (en) | Pharmaceutical composition for treating small cell lung cancer | |
CN117815387A (en) | Combination pharmaceutical composition of CDK4/6 inhibitor and anti-PD-L1 antibody | |
CN113993544A (en) | Multiple variable dose method for treating EGFR-high expressing cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |